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Metastasis is the leading cause of death in cancer patients because of the difficulty to 
treat the secondary tumors and the latency period between dissemination of metastatic 
cells from the primary tumor to other sites and clinical detection.  As such, metastasis 
accounts for a considerable bulk of the $100 billion yearly cost of cancer medical 
treatment. Understanding the mechanisms underlying metastasis events could have an 
enormous impact on patient survival rates and how clinicians and scientists target 
drugs to reduce metastasis. Targeting CTCs has garnered much attention as a 
therapeutic target in recent years. They are a bottleneck in the progressive stages of 
metastasis. My thesis explores how circulating tumor cells interact with the host 
environment and the host innate immune response that ensues. There are two host 
environments that I investigate 1) blood circulation where circulating tumor cells 
come in contact with white blood cells and 2) the inflammatory cells in a secondary 
organ, in this case the brain. My methods include extensive use of transgenic animal 
models, two-photon microscopy, bioluminescence imaging and imaging analysis. The 
work presented in this dissertation contributes information about how the innate 
immune system can be used as a therapeutic drug carrier to target CTCs.  
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 LIST OF ABBREVIATIONS 
 
2PEF two photon excited fluorescence 
CTCs circulating tumor cells 
ES E-selectin 
TRAIL TNF-related apoptosis-inducing ligand 
TNF tumor necrosis factor 
WBCs white blood cells (or leukocytes) 
BM brain metastasis 
PCa prostate cancer 
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CHAPTER 1 
INTRODUCTION AND ORGANIZATION OF DISSERTATION 
 
  3 
Introduction  
Metastasis is the leading cause of death in cancer patients because of the 
difficulty to treat the secondary tumors and the latency period between dissemination 
of metastatic cells from the primary tumor to other sites and clinical detection.  As 
such, metastasis accounts for a considerable bulk of the $100 billion yearly cost of 
cancer medical treatment (1). Understanding the mechanisms underlying metastasis 
events could have an enormous impact on patient survival rates and how clinicians and 
scientists target drugs to reduce metastasis.  
One way to achieve this is by understanding the impact of circulating tumor 
cells, which are a bottleneck in the progressive stages of metastasis. Circulating tumor 
cells (CTCs) represent a rare but volatile population of cells that are shed from the 
primary tumor into the bloodstream. CTCs have garnered much attention as a 
diagnostic target in recent years because increased amounts of CTCs found in a patient 
correlates with a poor prognosis. My thesis explores how circulating tumor cells can 
be used a therapeutic target to reduce metastasis. We find that CTCs are a highly 
effective therapeutic target and use of a E-selectin and Tumor necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) nanoparticle drug delivery vehicle 
effectively reduced CTC load within a single dose and in long-term administration 
results in a reduction of metastatic lesions (2, 3).  
Despite the promise of our therapeutic approach, the circulating tumor cell 
population was dramatically diminished but not eradicated.  Minimal residual disease 
(MRD) as this leftover population is often referred can acquire resistance to and re-
populate with a vengeance. This is an issue not only for the therapy presented in my 
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thesis but for all therapies. The latter part of my thesis creates an in vivo platform to 
explore how host organ microenvironment responds to an invading CTC, particularly 
in the brain which is a tightly regulated environment and often most complicated 
metastatic site to treat.  
The methods in this thesis include extensive use of transgenic animal models, 
advanced surgical preparations to mimic hematogenous spread of cancer, two-photon 
microscopy to allow for time-lapse imaging and deeper visibility into highly scattering 
tissue such as lung and lymphnode, bioluminescence imaging and imaging analysis. 
The work presented in this dissertation contributes information on the value of 
CTCs as a therapeutic target and demonstrate the use of the innate immune system as a 
carrier for therapeutic agents.  Secondly, the preliminary work on identifying key 
changes in the host organ microenvironment to invading CTCs could aid future 
investigators in how to target therapies. The ultimate goal is to identify cells in the 
microenvironment are that are the most crucial in either killing CTCs and/or 
maintaining a dormant state. This work spans the pre-clinical realm and also tries to 
understand basic principles behind metastasis.  
 
Organization of Dissertation  
The work in this dissertation centers on the use of circulating tumors cells 
(CTCs) and their role as a bottleneck for metastasis. In this text, we take advantage of 
CTCs using them as a therapeutic target and secondly to gain insight into how the host 
metastatic environment supports and/or undermines CTC completion of metastasis.  
  5 
Chapter 2: This chapter provides a general introduction to two-photon excited 
fluorescence microscopy and its superior value in in vivo imaging of dynamic 
processes such as cancer metastasis. Enclosed is a brief description of the process, 
history of its development, and a discussion of in vivo cellular labeling strategies.  
 
Chapter 3: This chapter outlines the prevalence and significance of studying 
cancer metastasis. The stages of metastasis are discussed with an emphasis on the role 
of circulating tumor cell population as a rate-limiting stage of this process.  
 
Chapter 4: This chapter introduces a nanomedicine formulation that can 
selectively target and kill cancer cells within the bloodstream. This therapy displays 
TNF-related apoptosis inducing ligand (Apo2L/TRAIL) and E-selectin adhesion 
receptor liposomes on the surface of circulating leukocytes where it will have 
increased contact opportunities with circulating tumor cells (CTCs). The therapy was 
exciting in that at least 75% of CTCs had been killed within 3 hours of drug 
circulation. These results were published in PNAS where I am a co-author.  
 
Chapter 5: In this chapter, we demonstrate an approach using nanoscale 
liposomes conjugated with E-selectin adhesion protein and Apo2L/TRAIL (TNF-
related apoptosis-inducing ligand) apoptosis ligand that attach to the surface of 
leukocytes and rapidly clear viable cancer cells from circulating blood, both in human 
blood samples and in the living mouse. For the first time, it is shown that such an 
approach can be used to prevent the spontaneous formation and growth of metastatic 
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tumors in an orthotopic xenograft model of prostate cancer, by greatly reducing the 
number of circulating tumor cells. We conclude that the use of circulating leukocytes 
as a carrier for the anti-cancer protein TRAIL could be an effective tool to directly 
target circulating tumor cells for the prevention of prostate cancer metastasis, and 
potentially other cancers that spread through the bloodstream. These results are 
currently in the submission pipeline where I am a co-first author.  
 
Chapter 6: This chapter outlines the study of circulating tumor cell metastasis 
into the brain microenvironment using 2PEF microscopy. Herein discussed are 
previous animal models used for studying circulating tumor cell extravasation into 
brain, and background on microglia activation in cancer. Finally, we discuss the 
preliminary results of the study on the role of microglia to circulating tumor cell 
metastasis into the brain microenvironment and future directions.  
 
Chapter 7: This chapter concludes the findings from the previous chapters and 
posits future directions pertaining to the work on CTC metastasis into the brain and 
the potential of CTC targeting for treating metastasis in a clinical setting.  
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CHAPTER 2 1 
TWO PHOTON EXCITED FLUORESCENCE MICROSCOPY 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
Permission to reproduce Figure 2.1 was granted by Elseiver. Svoboda, K., & Yasuda, 12 
R. (2006). Principles of Two-Photon Excitation Microscopy and Its Applications to 13 
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2.1 Power of the In Vivo approach 31 
In situ histology studies have generated essential information about cancer 32 
metastasis. However, this method only provides a single timepoint to explore the 33 
intended pathology in a single animal. This results in the use of large numbers of 34 
animals and inconsistency in data due to animal variability. Furthermore, with only a 35 
single timepoint, it is impossible to conclude the fate of the circulating tumor cell and 36 
vital spatial and temporal information is lost.  The real allure of in vivo experiments is 37 
the ability to observe phenomena as it occurs within an intact organism.  Two photon 38 
excited fluorescence (2PEF) microscopy provides the optical best platform to conduct 39 
in vivo imaging at the subcellular level.  In this chapter we give an overview of the 40 
history of 2PEF, a description of two-photon excitation processes, and the use of 2PEF 41 
microscopy for in vivo imaging of cancer metastasis processes. The imaging 42 
techniques discussed in this chapter are used primarily in Chapters 3 and 6.  43 
 44 
2.2 What is 2PEF? 45 
2PEF microscopy is a nonlinear optical technique that relies on the near 46 
simultaneous interaction of two photons with a single fluorophore. Two photons 47 
combine energies to excite a fluorophore to a higher energy state, much the same way 48 
a one-photon excitation process occurs. The excited fluorophore electron 49 
spontaneously relaxes, releasing a signal photon. Because this nonlinear interaction 50 
demands the near simultaneous interaction of two photons (~10-16s) with the same 51 
fluorophore, the process only occurs where the photon density is highest within the 52 
focal volume of a pulsed femtosecond laser beam. This provides intrinsic optical 53 
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sectioning, as fluorescent labels outside the focus are not excited. Any photon emitted 54 
can be attributed to the location of the laser focus. Therefore, an image volume may be 55 
generated voxel-by-voxel simply by scanning a sample in a raster fashion in three 56 
dimensions.  57 
58 
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 59 
 60 
Figure 2.1. Two-Photon Excitation Microscopy 61 
(A) Simplified Jablonski diagram of the 2PE process. (B) Localization of excitation in 62 
a scattering medium (black). The ex- citation beam (red) is focused to a diffraction- 63 
limited spot by an ob- jective where it excites green fluorescence in a dendritic branch, 64 
but not in a nearby branch. The paths of two ballistic photons and one scattered photon 65 
are shown (red lines). Scattered photons are too dilute to cause off-focus excitation. 66 
The intensity of the beam de- creases with depth as an increasing number of excitation 67 
photons are scattered. (C) Fluorescence collection in a scattering medium. 68 
Fluorescence photons are emitted isotropically from the excitation volume (red lines). 69 
Even scattered fluorescence photons contribute to the signal if they are collected by 70 
the objective. Since the field of view for de- tection is larger than for excitation, the 71 
fluorescence light exiting the objective back-aperture will diverge substantially 72 
(green). (D) Schematic of a 2PE microscope with epifluorescence and trans- 73 
fluorescence detection.  74 
 75 
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Two-photon excited fluorescence was first theorized by Maria Göppert-Mayer 76 
in the 1930s and the first designs for manipulating this process for a microscope was 77 
published in 1978 by Sheppard and R Kompfner(1). Despite the formulation of theory 78 
and designs, the power required to achieve sufficient photon densities for excitation 79 
would burn biological tissue. It wasn’t until the arrival of the femtosecond laser that 80 
2PEF in living tissue became a reality, with the first demonstration paper published in 81 
1990 by Winfried Denk, James Strickler, and Watt W. Webb (2) at Cornell University. 82 
Femtosecond lasers, though providing the high-energy flux needed, were still custom 83 
built, incredibly expensive, and challenging to operate and maintain. The first 84 
commercial 2PEF system wasn’t available until 1996 and was produced by Biorad 85 
Microsciences (3). The advancements in laser technology combined with the increased 86 
user-friendliness of commercial systems, has steadily made 2PEF an niche imaging 87 
tool for subcellular resolution imaging that had long been a obstacle for intravital 88 
imaging.  89 
 90 
2.3 Advantages of 2PEF  91 
2PEF has three distinct advantages for imaging within scattering media, the 92 
primary limitation for imaging tissue through optical methods. First, 2PEF excitation 93 
requires longer wavelengths that possess a longer scattering length, when compared 94 
with the short wavelengths used in one-photon imaging. Longer scattering length leads 95 
to higher penetration depth, as signal photons can travel further out of the tissue before 96 
their path is disrupted. The requirement for high photon density to generate signal in 97 
2PEF provides optical sectioning without the need for spatial filters (such as in 98 
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confocal microscopy) and increases detection efficiency (4). Furthermore, the low 99 
average power of the femtosecond excitation pulses reduces the amount of damage to 100 
cell structure and destruction of fluorescent molecules due to phototoxicity and 101 
photobleaching respectively. Differences in imaging capability between 2PEF and 102 
other optical imaging technique have been experimental demonstrated in numerous 103 
studies (5-8). Altogether, these advantages make it possible to chronically image 104 
individual cell populations deep within an intact, living organism which has breathed 105 
new life into our understanding of  the progression of cancer metastasis.  106 
 107 
108 
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 110 
 111 
 112 
 113 
 114 
 115 
Figure 2.2 Localization of excitation by two-photon excitation.  116 
(a) Single-photon excitation of fluorescein by focused 488-nm light (0.16 NA). (b) 117 
Two-photon excitation using focused (0.16 NA) femtosecond pulses of 960-nm light.  118 
 119 
 120 
 121 
 122 
 123 
 124 
 125 
 126 
 127 
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2.4 2PEF Imaging of Cancer Metastasis 129 
In the past, studies of metastasis relied on histological methods and end-point 130 
studies that only satisfy binary questions (did a metastasis form or did it not form) and 131 
does not yield insight into the process of cancer metastasis progression. 132 
Bioluminescence imaging provides whole animal long-term imaging, but has very low 133 
resolution (> 1mm) Video and confocal microscopy offer some intravital imaging 134 
capability but lack the resolution and imaging depth. 2PEF microscopy, combined 135 
with advanced surgical techniques and fluorescent dye capabilities, sheds light on the 136 
spatial and temporal dynamics of cancer progression and in particular, the role of the 137 
tumor microenvironment in the stages of metastasis (9-11). The use of surgically 138 
implanted organ windows provide long-term optical access while protecting tissue 139 
from the external environment, permitting observation in real-time of tumor cell 140 
intravasation, circulation, extravasation (12), and proliferation (13). We can observe 141 
tumor cell interactions with individual components of the microenvironment such as 142 
interaction with leukocytes, platelets, endothelial cells, and other stromal cells. 143 
Moreover, we can perturb these systems and use 2PEF to understand how genetic 144 
expression and cytokine signaling effect tumor cell involvement in the 145 
microenvironment (14, 15). Using 2PEF, we can begin to answer the question of how 146 
cancer cells metastasize in real-time. The impact of 2PEF microscopy on intravital 147 
imaging of cancer metastasis is unparalleled.  148 
In the metastasis model presented in Chapter 6, fluorescently labeled cancer 149 
cells were injected into the intracarotid artery on C57Bl6 transgenic mice expressing 150 
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GFP labeled microglia. With the aid of a previously implanted cranial window(16, 151 
17),  We use a custom built 2PEF microscope to image the transit of circulating tumor 152 
cells through brain parenchyma and correlate their ability to metastasize with the 153 
microglia activation response.  154 
155 
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 156 
 157 
 158 
 159 
Figure 2.3 Examples of 2PEF microscopy in highly scattering tissue. 160 
A) in vivo human endothelial cells (HCMEC, blue) interacting with brain vasculature 161 
(red). B) in vivo image of advanced glioblastoma (GBM-TSC, green) and newly 162 
developed vasculature (red). C) ex vivo image of COLO 205 cells (green) lodged into 163 
lung tissue (yellow). D) ex vivo image of dendritic cells (green) containing 164 
nanoparticles (red), in an intact lymph node. Collagen fibers (blue) in lymph node 165 
revealed from SHG signal.  166 
 167 
  18 
2.5 Cell Labeling Strategies for in vivo Imaging  168 
Labeling strategies become very important for imaging multiple cells 169 
populations involved in the study of cancer metastasis. With most microscope 170 
detection arrangements, a maximum of four colors can be separated into detection 171 
channels. In an optimal situation, each label appears in only one channel, clearly 172 
differentiating between cellular structures that may not be separable by visual 173 
inspection of the image. However, many dyes have broad emission spectra and as 174 
such, signal from one dye may appear in more than one channel. Although post 175 
imaging un-mixing algorithms can correct for this, if the morphology of the cells in 176 
question are visually similar, it may be difficult to distinguish cell populations in vivo. 177 
To overcome this challenge, use of multiple excitation wavelengths where the selected 178 
dyes have disparate absorption spectra can remove ambiguity.  179 
 180 
Prior to imaging, cells can be labeled endogenously or exogenously. 181 
Endogenous labeling includes insertion of fluorescent proteins (FP) into the cell 182 
genome. This method is typically very stable and allows visualization of cells after 183 
division since the FP is stably passed on to progeny. Exogenous labeling involves dye 184 
incorporation via cell uptake from its outside surroundings and is usually done 1 hour 185 
to 3 days prior to imaging. Dyes are mixed in with cell media and after an allotted 186 
amount of time are endocytosed into the cell cytosol. This method is ideal for short- 187 
term in vivo experiments or when using freshly isolated cells not suited for long-term 188 
cell culture. Often these dyes are using as tracking for quantitative analysis of cellular 189 
activity and compartmentalization. Label choice depends greatly on the experimental 190 
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setup. Table 1 lists dyes used in studies throughout my thesis along with optimal 191 
emission, excitation wavelengths and comments on usage.    192 
193 
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 194 
 195 
 196 
 197 
 198 
 Peak 2PE 
Absorption (nm) 
Peak 2PE 
Emission (nm) Common Use/Notes 
CMTMR 800 590 Cell labeling (cytosol) 
BCECF 
(Invitrogen) 800 526 
Cell labeling (cytosol) 
Not ideal label for ex vivo 
imaging. Cells lost 
fluorescence post-injection 
DiD/DiO/DiI 
(Invitrogen) 810 - 830 670/500/571 
Cell labeling (cytosol) 
Ideal for adoptive transfer 
studies 
Fluorescent 
Nanospheres 
Crimson red 
800 - 900 641-680 
Cell labeling; can be 
injected directly into 
vasculature for use as 
phagocytosis indicator 
Hoechst 33258 780nm-830nm 455nm 
Labels nuclei. Can be 
injected directly into 
vasculature to label all 
nuclei in bloodstream 
Table 2.1 Common fluorescent labeling strategies for 2PEF cellular 199 
imaging  200 
 201 
 202 
203 
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2.6 Conclusion 204 
 Since the inception of the femtosecond laser and the first published 205 
demonstration of two-photon microscopy (2, 3, 18) over 25 years ago, we have 206 
witnessed amazing discoveries within the field of cancer metastasis. Two photon 207 
excited fluorescence (2PEF) microscopy provides a large imaging depth, sub-cellular 208 
resolution, and a longer-term imaging capacity compared to other imaging modalities. 209 
Furthermore, it provides a unique capability to visualize processes occurring within 210 
intact tissue.  211 
 212 
A number of technological advancements within the imaging field have further 213 
enhanced imaging capability. The development of laser systems with longer infrared 214 
wavelengths allow us to image deeper and excite higher order nonlinear processes (19- 215 
21). Using the same optical configuration, we can simultaneously excite multiple 216 
nonlinear optical processes, such as harmonic generation (22), in addition to 217 
multiphoton processes. This is of particular significance when considering the 218 
fluorescence of collagen under second harmonic generation (SHG) (23-26) and myelin 219 
under third harmonic generation (THG) (27). More sophisticated detection systems 220 
collect and separate sample fluorescence to provide greater spectral resolution, 221 
facilitating the practical observation of more fluorescent dyes.   222 
 223 
What was once a highly specialized imaging technique has become more 224 
accessible, making it possible for more non-optical scientists to use. There are now 225 
many  popular commercial 2PEF microscopes, including the Ultima series (Bruker), 226 
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LSM780 (Zeiss), and FluoView FV1000-MPE (Olympus). While commercial sources 227 
provide easy access they are often constructed in a standardized way that provides 228 
little room for adjustments. Individual laboratories are also making completely 229 
customizable microscopes such as the Parker Lab (UC Irvine) and the microscopes 230 
built and used in the Schaffer-Nishimura Labs.  2PEF microscopy has become a key 231 
visualization tool. Combined with the increasing development of transgenic mouse 232 
models, an ever-expanding catalog of fluorescent dyes and proteins (28), and 233 
sophisticated detection systems, we are now able to answer questions that were never 234 
possible before in the physiologically relevant in vivo system.  235 
 236 
237 
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CHAPTER 3 
CIRCULATING TUMOR CELLS 
 
 
 
 
Permission to reproduce Table 3.1 was granted by American Cancer Society. 
Cancer Facts & Figures 2015. Atlanta: American Cancer Society; 2015.  
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3.1 Prevalence and Clinical Significance 
Metastasis is the state of disease when a primary tumor has disseminated to 
other organs to form secondary tumors. Metastatic cancers are more difficult to treat 
than primary tumors due to vast genetic differences and their ability to remain dormant 
for years before becoming clinically apparent. Moreover, the majority of cancer 
treatments only target cancer growth rather than cancer spread. As such, metastasis is 
a major problem, accounting for over 90% of cancer-related deaths (1). In addition, 
the 5-year survival rate (Table 1) decreases dramatically for tumors that are detected 
distantly. In the case of prostate cancer, 99% of patients reach the 5-year survival 
landmark if detected locally whereas the prognosis decreases to 23% (2). Much 
research has been devoted to understanding the metastatic process in an effort to gain 
insight into the best therapeutic targets to contain and prevent its spread.  
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Table 3.1 Five-year Relative Survival Rates by Stage at Diagnosis, US, 
2004-2010.  
Adapted from American Cancer Society. Cancer Facts & Figures 2015. Atlanta: 
American Cancer Society; 2015. 
  
 
 
Five-Year Relative Survival Rates 
 Local Disseminated 
Breast 99 25 
Colon & Rectum 90 13 
Pancreas 26 2 
Prostate 99 28 
Stomach 64 4 
Ovary 92 27 
Melanoma 98 16 
Kidney 92 12 
Oral Cavity 83 37 
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3.2 Stages of Metastasis 
Metastasis is a highly complex and inefficient process that can be characterized 
in five stages, invasion, intravasation, circulation, extravasation, and proliferation 
(Figure 1). First, tumor cells undergo invasion; the migration of cells from the primary 
tumor mass in response to a chemical and/or oxygen gradient. Next, migrating cells 
intravasate into the blood circulation where they are commonly referred to as 
circulating tumor cells (CTCs). Lymphatic intravasation also occurs, however to a 
lesser extent. Many CTCs can be shed from a primary tumor but most are unable to 
withstand the force of circulation and die. Small numbers of CTCs are able to 
extravasate, exiting the blood and/or lymphatic circulation to enter a secondary organ. 
Upon extravasation, cells can die, enter a dormant non-proliferative state, or continue 
to proliferate into what finally becomes a metastatic lesion. Although these steps are 
described as a progression, it is likely that metastasis occurs as a loop. A new batch of 
CTCs can be shed, just as older ones extravasate into a secondary organ.  This reality 
is all the more relevant since current imaging technologies may not reveal the presence 
of a micrometastasis at the time of diagnosis.  
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Figure 3.1 Diagram of the Stages of Metastasis 
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Therapeutically, each stage can be seen as a target to limit and prevent 
metastasis process. Eliminating metastatic cells at any step in the process, has the 
ability to prevent proliferation at a secondary site and associated poorest clinical 
outcome. Many drugs that attempt to do just that. Bevacizumab targets intravasation 
by inhibiting angiogenesis (3). MMP inhibitors like Prinomastat and Metastat, prevent 
cancer cells from being able to degrade extracellular matrix, a process that is known to 
promote both intravasation and extravasation in preclinical animal models (4). 
Disappointingly, MMP inhibitors have not shown efficacy in human clinical trials (5) 
and drugs that target angiogenesis are effective in limiting tumor growth but only lead 
to dormancy rather than a real cure (6). The remainder of this chapter explores how 
targeting CTCs while in the circulation environment can eliminate metastasis.  
 
3.3 Circulating Tumor Cells 
CTCs are a rare cell population with monumental consequences for cancer 
progression and treatment. CTCs are secreted from a primary tumor, travel through the 
circulation, and ultimately extravasate into a second organ. Depending on the origin of 
cancer and the disease stage, up to 1 million cells can be shed per gram of tumor per 
day (7). This cell shedding also can occur in a temporally inconsistent pattern (8).  
CTCs are a bottleneck form metastasis, since cells must breakaway from the primary 
tumor and travel through the blood or lymphatic circulation to form a successful 
metastasis in another organ. This poses great possibilities to manipulate and monitor 
CTCs for cancer treatment.  
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3.4 Circulating Tumor Cells as Clinical Prognosis Marker  
CTCs are a useful prognosis marker because they can be used as an indicator 
of cancer disease progression. CTCs can be found within the bloodstream before the 
primary tumor is detectable, after primary tumor resection and can appear before 
tumor recurrence (9, 10). Still, the significance of these circulating cells is still debated 
due to the inhomogeneity of CTC enumeration results not only amongst patients, but 
amongst measurement technologies.   
 
Great efforts have been made to isolate and characterize circulate tumor cells 
from patient samples; Finding CTCs is a needle in a haystack problem. In half liter of 
blood there are approximately 6 billion white blood cells (leukocytes), over 3 trillion 
red blood cells (11), whilst only 1-8 CTCs. Multiple attempts have been made to 
isolate CTC by using physical or labeling procedures (8, 12-14). However, variability 
in the sensitivity and specificity of each capturing device to employ different criteria, 
makes the isolation of CTCs extremely difficult (15). In addition, a trained observer 
often verifies isolated CTCs which introduces another element for variability. One of 
the most trusted sources for CTC isolation is CellSearch, which has the first and only 
FDA-approved CTC testing kit.  The CellSearch CTC strategy uses immunomagnetic 
assays to fluorescently select for cells that contain a nuclei, cytokeratin labeling 
(marker for cells of epithelial origin) and are negative for CD45 (a global marker for 
leukocytes) (16).  
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Caution should however be given to the interpretation of CTC counts. CTC 
shedding can occur sporadically, increasing the possibility of a false reading. Every 
assay has a limitation, also leading to the possibility labeling normal cells as CTC and 
vice versa. Questions remain about the significance of analyzing isolated CTCs. The 
answer is complicated because captured CTCs do not necessarily represent successful 
metastasis. This is corroborated by studies that show a significant proportion of 
isolated and detected CTCs to be apoptotic (17). CTCs can undergo cell death at any 
stage of metastasis. Therefore, the few that persist acquire survival mutations and to 
contain a genetically different profile in comparison to the primary tumor.  Bypassing 
the variability amongst isolation methods, enumerating CTCs has allowed clinicians to 
determine patient prognosis and therapy efficacy (18). The number of detected CTCs, 
is consistently correlated with a shortened lifespan (19-21).   
 
3.5 Circulating Tumor Cells as a Therapeutic Target 
CTC research has centered on their utility as a diagnostic, yet CTCs maybe be 
equally if not more valuable as a therapeutic target.  The circulation stage is an ideal 
period to target metastasis because CTCs are highly sensitive due to a lack of 
anchorage proteins and the high stress environment of the bloodstream. This is 
supported by studies demonstrating that CTCs are more sensitive to apoptosis 
inducing drugs whilst unanchored (22, 23). Manipulating CTCs for therapeutic benefit 
remains in its infancy, however the advancement in strategies for targeting and 
eliminating CTCs are elaborate and promising (7, 24). This includes in vivo 
implantable devices that detect CTCs in patients including the use of thin stainless 
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steel wire (25), vein indwelling needle system (26) and cell capture tubes (27). Most 
of these devices are limited by the risk of infection, clots, and anatomical design. To 
eliminate some of these risks, some devices function ex vivo similar to dialysis 
machines where externally filtered blood is returned to the patient in a closed system. 
While these systems show efficacy in detecting and filtering CTCs, the devices have 
to be removed periodically and do not provide continuous control of CTC populations. 
  
While the previously mentioned therapies employ implantation of medical 
devices, improvements in our understanding of metastasis biology and advancements 
in nanomedicine, have enabled greater specificity to target CTCs. Nanoparticles 
synthesized from polymers, liposome, or heavy metals, can be loaded with therapeutic 
drugs and used as nanocarriers (28). Wide selection of nanoparticle materials available 
allow design of particles that can control the duration of drug release and match 
particle size to tumor pore size(29). Nanoparticles can be tagged with ligands to confer 
binding specificity to target cells. The challenge of nanoparticle therapy is that these 
particles are distributed passively and may not accumulate in desired areas. Targeting 
nanoparticles to immune cells evades this problem tumor infiltration and cell-based 
nanoparticle therapies are increasing in use (30-34). In this dissertation, CTCs are 
targeted via nanoparticles delivered on the surface of circulating immune cells (33, 
35). As these new techniques come to fruition, CTC therapeutics could very well halt 
the nature of metastatic disease progression and ultimately how clinicians provide 
cancer treatment.  
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CHAPTER 4 1 
TRAIL-COATED LEUKOCYTES THAT KILL CANCER CELLS 2 
IN THE CIRCULATION 3 
 4 
In this chapter, we present a study that investigates a unique approach to target 5 
and kill colon and prostate cancer cells in the blood that causes circulating leukocytes 6 
to present the cancer-specific TNF-related apoptosis inducing ligand (TRAIL) on their 7 
surface along with E-selectin adhesion receptor. This approach demonstrated in vitro 8 
with human blood and also in mice, mimics the cytotoxic activity of natural killer cells 9 
and increases the surface area available for delivery of the receptor-mediated signal. 10 
The resulting “unnatural killer cells” hold promise as an effective means to neutralize 11 
circulating tumor cells that enter blood with the potential to form new metastases. 12 
The following text contains the entire study as I thought it would put my 13 
contribution in better context. My specific contribution to the study was using two- 14 
photon excited fluorescence (2PEF) microscopy to enumerate live and dead 15 
circulating tumor cells lodged in lung tissue, and performed all of the animal 16 
experiment data, shown in Figures 2, 5, and 6.  17 
This work is published in Proceedings of the National Academy of the 18 
Sciences. The manuscript can be found with the following citation:  19 
Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR (2014) TRAIL-coated 20 
leukocytes that kill cancer cells in the circulation. Proceedings of the National 21 
Academy of Sciences 111(3):930–935. 22 
 23 
 24 
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4.1 Introduction 29 
Over 90% of cancer-related deaths are due to cancer metastasis, the spread of 30 
cancer cells from a primary tumor to anatomically distant organs (1). In many types of 31 
cancer, cancer cells from the primary tumor can intravasate into the peripheral 32 
circulation as circulating tumor cells (CTCs) (2, 3). These CTCs can then interact with 33 
the receptor-bearing endothelial cell wall under flow in other organs, in a manner 34 
similar to leukocyte extravasation during inflammation and lymphocyte homing to 35 
lymphatic tissues (4). Recent studies have shown that CTCs from many types of 36 
primary tumors express sialylated carbohydrate ligands similar to leukocytes, which 37 
mediate interactions with selectins on the endothelium (5, 6). Selectins possess rapid, 38 
force-dependent binding kinetics, which can trigger the rolling adhesion of CTCs 39 
along the blood vessel wall (7, 8). CTCs can subsequently transition from rolling to 40 
firm adhesion, allowing for transendothelial migration into tissues and eventual 41 
formation of micrometastases (9). Surgery and radiation have proven effective at 42 
treating primary tumors that do not invade the basement membrane; however, the 43 
difficulty of detecting distant micrometastases has made the majority of metastatic 44 
cancer treatments unsuccessful.  45 
The development of technologies to directly target CTCs in vivo holds promise 46 
in reducing both the metastatic load and the formation of new tumors. Although 47 
studies have reported that as many as 1 × 106 cancer cells detach from the primary 48 
tumor (per gram) of patients per day (10, 11), CTCs are difficult to detect due to their 49 
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sparse concentrations in the bloodstream, as low as 1–100 cells per mL (3, 12). 50 
Additionally, there are ∼1 × 106 leukocytes or 1 × 109 erythrocytes per single CTC in 51 
blood (13). Despite the difference in numbers, both leukocytes and CTCs share similar 52 
characteristics in terms of their migration within the bloodstream. Highly deformable 53 
erythrocytes experience a drift velocity away from the vessel wall and collect in the 54 
center region, displacing less deformable leukocytes and CTCs to the near-wall region 55 
in a mechanism termed margination (14). Such margination phenomena can 56 
effectively surround CTCs within the circulating leukocyte population, thus making 57 
leukocytes a potentially attractive carrier of treatments to CTCs by exploiting  58 
The utilization of leukocytes to treat CTCs directly within the bloodstream has 59 
not previously been explored. Here, we describe a therapeutic approach to target and 60 
kill circulating cancer cells in the bloodstream by functionalizing leukocytes with the 61 
apopto- sis-inducing ligand TRAIL, and the adhesion receptor E-selectin directly 62 
within blood under shear flow. The functionalization of leukocytes under flow, 63 
effectively creating a form of “unnatural killer cells” within the bloodstream, is shown 64 
to be highly effective at treating circulating cancer cells in flowing human blood in 65 
vitro, and in the peripheral circulation of mice in vivo.  66 
 4.2.1 E-Selectin /TRAIL Liposomes Adhesively Interact and Induce 67 
Apoptotic Cancer-Cell Death Under Shear Flow. 68 
Many types of circulating tumor cells (CTCs) and cancer cell lines derived 69 
from colon, breast, prostate, and pancreas are known to display glycosylated ligands 70 
that allow them to adhesively interact with E-selectin (ES) under physiological shear 71 
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flow (15). This interaction has been proposed to explain why some cancers home to 72 
tissue-specific capillary beds such as the bone marrow and liver (16, 17). In an attempt 73 
to target and kill cancer cells of this form, nanoscale liposomes conjugated with a 74 
mixture of recombinant human ES protein and tumor necrosis factor (TNF)-related 75 
apoptosis-inducing ligand (TRAIL) were developed (Fig. 1A, Fig. S1, and Table S1). 76 
TRAIL binds to death receptors 4 and 5 on the surface of cancer cells to induce 77 
apoptosis through the intrinsic and extrinsic pathways (18, 19). ES/TRAIL liposomes 78 
consisting of a 10% weight ratio of (1,2-dioleoyl-sn-glycero-3-{[N-(5-amino-1- 79 
carboxy-pentyl) iminodiacetic acid] succinyl}(nickel salt) (DOGS-Ni-NTA), used to 80 
conjugate ES and TRAIL to the liposome surface, were found to be most effective at 81 
inducing apoptotic cell death in a colorectal adenocarcinoma (COLO 205) cell line 82 
under static conditions (Fig. S2), as determined using an Annexin-V apoptosis assay.  83 
In the postcapillary venules where selectin-mediated adhesion and cell 84 
extravasation into tissues typically occur, moderate shear rates can initiate flowing cell 85 
interactions with the endothelial cell wall (20, 21). To recreate these physical forces in 86 
vitro, a cone-and-plate shear assay was developed to probe the inter- actions of cancer 87 
cells and ES/TRAIL liposomes under venular shear rates. After exposure to shear flow 88 
(shear rate: 188 s−1) for 2 h, COLO 205 cells exposed to ES liposomes displayed their 89 
normal morphology whereas substantial membrane blebbing was observed in samples 90 
exposed to ES/TRAIL liposomes, characteristic of cells undergoing apoptosis (Fig. 91 
1B). Annexin-V assay revealed that exposure to shear flow for 2 h induced minimal 92 
COLO 205 cell apoptosis in untreated controls (Fig. 1C), in addition to treatment with 93 
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liposomes in the absence of conjugated protein (Fig. 1D) or conjugated solely with ES 94 
(Fig. 1E) or TRAIL (Fig. 1F). However, a combination of ES/TRAIL conjugated to 95 
the liposome surface induced a significant decrease in COLO 205 vi- ability following 96 
exposure to shear flow (Fig. 1 G and H). 97 
98 
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 99 
Figure 4.1 ES/TRAIL liposomes adhesively interact with and kill 100 
cancer cells under uniform shear flow. 101 
 (A) Synthesis of ES, TRAIL, and ES/TRAIL uni- lamellar liposomes using a thin 102 
film hydration method. Briefly, lipids in chloroform were dried overnight to form a 103 
thin lipid film. Lipids were then hydrated and subjected to freeze–thaw cycles to form 104 
multilamellar liposomes, which were extruded through membranes to form 105 
unilamellar liposomes. ES, TRAIL, or a combination of ES and TRAIL was then 106 
conjugated to Ni-NTA on the liposome surface. To assess the ability of ES/TRAIL 107 
liposomes to target and kill cancer cells under flow, ES/TRAIL liposomes were added 108 
to a suspension of COLO 205 cancer cells and exposed to shear flow in a cone-and- 109 
plate viscometer at a shear rate of 188 s−1 for 2 h. Cells were then removed, washed, 110 
placed into culture for 24 h, and assessed for cell viability. (B) COLO 205 111 
morphology after treatment with ES (Upper) and ES/TRAIL (Lower) liposomes under 112 
shear flow. (Scale bar, 20 μm.) (C–G) Representative propidium iodide/Annexin-V 113 
flow cytometry plots of unsheared cancer cells (C) and cells sheared with naked (D), 114 
TRAIL-bound (E), ES-bound (F), and ES/TRAIL-bound liposomes (G) under shear 115 
flow. Cells were classified into four categories based on dye uptake: viable cells 116 
[negative for Annexin-V and propidium iodide (PI)], early apoptotic cells (posi- tive 117 
for Annexin-V only), late apoptotic cells (positive for Annexin-V and PI), and necrotic 118 
cells (positive for PI only). (H) Percent of viable cells after treatment for each group. n 119 
= 3 for all samples. Bars represent the mean ± SD in each treatment group. ***P < 120 
0.0001 (one-way ANOVA with Tukey posttest).  121 
122 
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 To investigate the adhesive characteristics of ES/TRAIL liposomes to cancer 123 
cells under flow, COLO 205 cells were ex- posed to ES/TRAIL liposomes consisting 124 
of fluorescent cholesterol and exposed to shear flow as in previous in vitro shear 125 
assays. Flow cytometry revealed that >99.9% of the COLO 205 cell population was 126 
adhered to ES/TRAIL liposomes after exposure to shear flow (Fig. S3 A and B). 127 
Fluorescent micrographs and brightfield overlay images clearly displayed ES/TRAIL 128 
liposomes adhered to the surface of COLO 205 cells (Fig. S3 C and D). These data 129 
suggest that the presence of the ES adhesion receptor enhances the effect of TRAIL by 130 
promoting tighter contacts with the cancer-cell membrane.  131 
4.2.2 ES/TRAIL Liposomes Functionalize Leukocytes in Whole Blood 132 
Under Shear Flow in Vitro.  133 
 134 
In addition to CTCs, circulating leukocytes also possess ligands for ES, which 135 
are necessary in the inflammatory response and lymphocyte homing to lymphatic 136 
tissues (1, 22). To assess the potential to functionalize leukocytes with ES/TRAIL to 137 
target and kill CTCs, we treated human blood with fluorescent ES/TRAIL liposomes 138 
under shear flow in a cone- and-plate viscometer. Upon exposure to shear (shear rate: 139 
188 s−1), ES/TRAIL liposomes readily bind to leukocytes via selectin ligands on the 140 
leukocyte surface (Fig. 2A).  141 
142 
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 143 
Figure 4.2 ES/TRAIL liposomes adhere to multiple leukocyte 144 
subpopulations after exposure to shear flow in whole blood.  145 
(A) Confocal images of ES/TRAIL liposomes (green) bound to human leukocytes 146 
(blue, cell nuclei) after ex- posure to shear flow in whole blood in a cone-and-plate 147 
viscometer at 188 s−1 for 30 min. Leukocytes have nuclear morphology characteristic 148 
of monocytes (Left), lymphocytes (Center), and neutrophils (Right). (Scale bar, 5 μm.) 149 
(B–G) To assess the adhesion of ES/TRAIL liposomes to leukocyte subpopulations, 150 
fluorescent ES/TRAIL liposomes were added to human blood and exposed to shear 151 
flow in a cone-and-plate viscometer at a shear rate of 188 s−1 for 30 min. Leukocytes 152 
were isolated from blood using a Polymorphs density gradient and labeled with CD3, 153 
CD14, CD16, CD19, and CD56, which is typically expressed on T lymphocytes, 154 
monocytes, neutrophils, B-lympho- cytes, and natural killer cells, respectively. 155 
Expression of fluorescent ES/TRAIL (FL ES/TRAIL) liposomes on the surface of 156 
leukocytes that are CD3+ (B), CD14+ (C ), CD16+ (D), CD19+ (E ), and CD56+ (F ), 157 
determined using flow cytometry. Expression of CD3, CD14, CD16, CD19, and CD56 158 
on the leu- kocyte surface was determined using isotype controls. No label, unsheared 159 
cells that were not treated with fluorescent ES/TRAIL liposomes; ES Block, cells 160 
treated with fluorescent ES/TRAIL liposomes that were pretreated with an ES 161 
functional blocking antibody; Post-Mix, cells labeled with fluorescent ES/TRAIL 162 
liposomes immediately after mixing liposomes in whole blood. (G) Percent of CD3+, 163 
CD14+, CD16+, CD19+, and CD56+ leukocytes adhered to ES/TRAIL liposomes. n = 164 
3 for all samples. Bars represent the mean ± SD in each treatment group. ***P < 165 
0.0001 (one-way ANOVA with Tukey posttest).  166 
167 
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To quantify leukocyte subpopulations that adhere to ES/TRAIL liposomes 168 
under flow, leukocytes were separated from whole blood and analyzed for both 169 
leukocyte marker expression and adherent ES/TRAIL liposomes using flow 170 
cytometry. Functionalized leukocytes were labeled with CD3, CD14, CD16, CD19, 171 
and CD56 antibodies, as such markers are commonly expressed on most T 172 
lymphocytes, monocytes, neutrophils, B-lymphocytes, and natural killer (NK) cells, 173 
respectively (23). Minimal adhesion of ES/TRAIL liposomes to leukocytes in blood 174 
was observed in the presence of a functional blocking ES antibody (Fig. 2 B–G). 175 
Minimal ES/TRAIL liposome adhesion was also observed immediately after treatment 176 
with whole blood. However, after exposure to shear flow, flow cytometry analysis 177 
revealed that leukocyte subpopulations positive for CD3 (Fig. 2B), CD14 (Fig. 2C), 178 
CD16 (Fig. 2D), CD19 (Fig. 2E), and CD56 (Fig. 2F) adhered to ES/TRAIL 179 
liposomes to varying degrees (Fig. 2G). Adhesion was also observed on populations 180 
of lymphocytes, which suggests that some cytotoxic patrolling of the lymphatic 181 
system may also occur in vivo. Leukocyte subpopulations can vary in their E- selectin 182 
ligand expression (24) and thus could explain the variations in the number of bound 183 
ES/TRAIL liposomes.  184 
4.2.3 ES/TRAIL Functionalization Does Not Induce Significant 185 
Leukocyte or Endothelial Cell Death.  186 
 187 
To assess the effects of ES/TRAIL functionalization on leukocyte viability, 188 
mononuclear leukocytes isolated from human blood were treated with ES/TRAIL 189 
liposomes under both static and shear-flow conditions. Annexin-V assays revealed no 190 
significant differences in leukocyte viability when leukocytes were incubated with ES 191 
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(Fig. S4B) or ES/TRAIL (Fig. S4C) liposomes under static conditions for 24 h, 192 
compared with untreated leukocyte controls (Fig. S4 A and D). Upon 193 
functionalization with liposomes under shear flow for 2 h (shear rate, 188 s−1), no 194 
significant decreases were found in ES (Fig. S4F) or ES/TRAIL (Fig. S4G) 195 
functionalized leukocytes, compared with untreated leukocyte controls (Fig. S4 E and 196 
H). These data suggest that ES/TRAIL liposomes can functionalize leukocytes under 197 
flow to target and kill cancer cells, while exerting negligible cytotoxic effects on 198 
leukocytes. It is important to note that individual subpopulations of leukocytes have 199 
shown apoptotic effects in the presence of TRAIL (25); however, this study focused 200 
on the overall effects of ES/TRAIL liposomes on blood- borne leukocytes.  201 
To assess the effects of ES/TRAIL functionalization on endothelial cell 202 
viability, human umbilical vein endothelial cells (HUVECs) were treated with 203 
ES/TRAIL liposomes in human blood under shear-flow conditions in vitro. Treatment 204 
with ES/ TRAIL liposomes or an equivalent concentration of soluble TRAIL in human 205 
blood under shear flow for 4 h induced no significant differences in HUVEC viability, 206 
compared with un- treated HUVECs exposed to shear in human blood (Fig. S5). These 207 
data suggest that ES/TRAIL-functionalized leukocytes exert negligible toxic effects on 208 
human endothelial cells under blood-flow conditions.  209 
4.2.4 Apoptotic Effects of ES/TRAIL Therapy Are Enhanced in 210 
Human Blood Under Flow 211 
 212 
 Clinically, CTCs are sparsely distributed in the complex milieu of whole 213 
blood, at concentrations as low as 1–100 cells per mL (3, 12). To examine whether 214 
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ES/TRAIL liposomes would effectively target cancer cells in the presence of blood 215 
cells and serum under flow conditions, we fluorescently labeled colorectal COLO 205 216 
and prostate PC-3 cancer-cell lines and spiked them into human peripheral blood. 217 
Surprisingly, under identical shear-flow conditions, ES/TRAIL therapy was even more 218 
effective at killing cancer cells in the presence of human blood (Fig. 3 A–D), 219 
compared with shearing COLO 205 or PC-3 cells alone in buffer (Fig. 3E), with <5% 220 
of the fluorescent, viable cancer-cell populations remaining after ES/TRAIL treatment 221 
(Fig. 3E). These results suggest that ES/TRAIL therapy is effective at targeting 222 
circulating cancer cells derived from multiple organs in human blood.  223 
224 
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Figure 4.3 ES/TRAIL liposome therapeutic effects are enhanced in 238 
human blood under flow in vitro.  239 
(A) Flow cytometry of COLO 205 cancer cells after treatment with ES/TRAIL or ES 240 
liposomes in blood under shear flow in a cone-and-plate viscometer at 188 s−1 for 2 h. 241 
Unsheared, viable untreated cancer cell control. (B) Representative flow cytometry 242 
histogram showing the number of viable cancer cells collected. (C) Representative 243 
micrographs of COLO 205 cells (white) in blood when treated with ES/TRAIL (Left) 244 
and ES only (Right) liposomes in blood under shear flow. (Scale bar, 50 μm.) (D) 245 
Number of viable COLO 205 and PC-3 cells per volume of blood after treatment with 246 
ES/TRAIL or ES liposomes in blood under shear flow. n = 3 for all samples. Bars 247 
represent the mean ± SD in each treatment group. **P < 0.001, ***P < 0.0001 248 
(unpaired t test). (E) Comparison of fraction of COLO 205 and PC-3 cells that 249 
remained viable after treatment with ES/TRAIL liposomes in buffer versus blood. n = 250 
3 for all samples. Bars represent the mean ± SD in each treatment group. ***P < 251 
0.0001 (unpaired t test). (F) Fraction of COLO 205 and PC-3 cells that remained 252 
viable after treatment with ES/TRAIL lip- osomes in blood with varying percentages 253 
of normal hematocrit. Hematocrit was varied whereas other blood components 254 
remained constant, based on a normal hematocrit of 45%. Plasma indicates removal of 255 
all blood cells. n = 3 for all samples. Bars represent the mean ± SD in each treatment 256 
group. *P < 0.05 (one-way ANOVA with Tukey posttest).  257 
258 
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To evaluate the impact of blood cells on the efficacy of ES/ TRAIL treatment, 259 
fluorescent COLO 205 and PC-3 cells were spiked in human blood of varying 260 
hematocrit percentages. All additional blood-cell components were maintained 261 
whereas the volume of removed erythrocytes was replaced with plasma from the same 262 
blood donor. Interestingly, the apoptotic effects were hematocrit-dependent, as higher 263 
hematocrit significantly de- creased the number of viable COLO 205 and PC-3 cells 264 
after ES/ TRAIL treatment (Fig. 3F). The enhanced apoptotic effect suggests that 265 
blood-cell collisions under flow can promote the apoptotic effects of ES/TRAIL 266 
liposomes and agrees with our intuitive understanding of blood rheology, as the 267 
presence of erythrocytes is known to create erratic cell paths with frequent cross- 268 
streamline displacements (26) and increase the lifetime of colliding doublets to 269 
promote aggregate formation (27).  270 
To assess the mechanism by which leukocytes act as a pervading carrier 271 
surface for functional TRAIL, blood was pretreated with ES/TRAIL liposomes under 272 
shear flow, with blood cells subsequently separated from unbound ES/TRAIL via 273 
centrifugation and replaced with fresh blood plasma. ES/TRAIL therapeutic effects 274 
under shear flow remained nearly identical, as COLO 205 and PC-3 cells, spiked into 275 
a suspension of blood with washed, pretreated blood cells, were killed at roughly the 276 
same rate as unwashed blood (Fig. 4 A–C). Thus, upon addition of the ES/ TRAIL 277 
liposomes to cancer cell-spiked blood, liposomes attach to the surface of leukocytes 278 
and are available for inducing apoptosis in cancer cells that they come into contact 279 
with (Fig. 4 D and E). As an indicator of unbound ES/TRAIL liposomes and/or 280 
liposome fragments remaining in human blood after shearing pretreatment, the toxicity 281 
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of supernatant collected from pretreated blood was tested in COLO 205 culture. An 282 
Annexin-V assay showed min- imal COLO 205 cell death after treatment with a 283 
supernatant of human plasma and unbound ES/TRAIL, compared with cells treated 284 
with plasma supernatant alone (Fig. S6). These data suggest that ES/TRAIL liposomes 285 
readily bind to the surface of leukocytes, with minimal unbound liposomes remaining 286 
to target and kill cancer cells under flow. 287 
288 
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 289 
  290 
Figure 4.4 ES/TRAIL liposomes functionalize leukocytes under shear flow in 291 
vitro to target and kill cancer cells. (A) Flow cytometry plots of COLO 205 cells in 292 
untreated samples (Left) and when treated in human blood with ES (Center) or 293 
ES/TRAIL (Right) functionalized leukocytes (but no unbound liposomes) under shear 294 
flow. (B and C) Number of viable COLO 205 (B) and PC-3 (C) cells per volume of 295 
blood after treatment with leukocytes func- tionalized with ES/TRAIL or ES 296 
liposomes, but with no unbound liposomes, in human blood (Washed), or after 297 
treatment with ES or ES/TRAIL liposomes in blood (Unwashed). n = 3 for all 298 
samples. Bars represent the mean ± SD in each treatment group. **P < 0.001, ***P < 299 
0.0001 (unpaired t test). (D and E) Schematic of the two-step mechanism involving 300 
decoration of leuko- cytes with liposomes (D), which then contact circulating cancer 301 
cells and activate the death receptor (E).  302 
303 
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4.2.5 ES/TRAIL Functionalized Leukocytes Reduce Number of 304 
Viable Cancer Cells in Mouse Circulation in Vivo.  305 
 306 
To assess and compare the cytotoxic effects in vivo with our previous results in 307 
vitro, ES/ TRAIL liposomes were also tested for their ability to kill cancer cells 308 
flowing in the peripheral circulation of mice. Two million fluorescently labeled COLO 309 
205 cells were injected into the tail vein of immunocompetent C57BL/6J mice, 30 min 310 
after injection of 120 µL of either ES/TRAIL liposomes, ES liposomes, or soluble 311 
TRAIL (Fig. 5A). Tail-vein injection was used to model leukocyte/CTC interactions 312 
in mouse circulation, as this technique has been an accepted and widely used model of 313 
lung metastasis (28–31) since the pioneering work of Fidler et al. (32– 34). For these 314 
studies, the use of recombinant human E-selectin was continued because of its ability 315 
to bind both human COLO 205 cancer cells and mouse neutrophils, which were 316 
previously shown to have cross-reactivity and roll on E-selectin (35). Mice were killed 317 
2.5 h after the initial injection, and cancer cells were recovered from the circulation 318 
via cardiac puncture. Cancer cells were placed back into culture for 2–3 h before the 319 
number of viable cells was quantified.  320 
Using flow cytometry, we measured ∼130,000 cancer cells per mL of blood for 321 
mice injected with control ES liposomes, compared with <2,000 cancer cells per mL 322 
of blood surviving from ES/TRAIL-treated mice (Fig. 5 B and C). Mice injected with 323 
buffer or soluble TRAIL had intermediate numbers of cells (Fig. 5C) compared with 324 
ES and ES/TRAIL-treated samples, likely indicating that ES functionalized liposomes 325 
help to retain cancer cells in the circulation by blocking selectin-mediated interaction 326 
of the COLO 205 cells with the endothelium. Brightfield micrographs of COLO 205 327 
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cells exposed to buffer and soluble TRAIL showed characteristic cancer-cell 328 
morphology (Fig. 5D). Micrographs of COLO 205 cells exposed to ES revealed 329 
adherent leukocytes on the COLO 205 cell surface without significant morphological 330 
change whereas the cancer cells from ES/TRAIL- treated mice showed notable 331 
membrane blebbing of COLO 205 cells in the proximity of leukocytes (Fig. 5D). To 332 
assess the adhesion of ES/TRAIL liposomes to leukocytes in mouse circulation, mice 333 
were injected with ES/TRAIL liposomes containing fluorescent cholesterol and were 334 
allowed to circulate for 2.5 h. Brightfield overlay micrographs showed that leukocytes 335 
recovered from the mouse circulation were functionalized with ES/ TRAIL liposomes 336 
(Fig. 5E), suggesting that ES/TRAIL remains functionalized to leukocytes, which can 337 
exert cytotoxic effects onto cancer cells in mouse circulation.  338 
339 
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Figure 4.5 ES/TRAIL functionalized leukocytes target and kill cancer 343 
cells in the circulation of mice in vivo.  344 
(A) Schematic of in vivo mouse experiment. (B) Flow cytometry of untreated COLO 345 
205 cancer cells (Left) and those re- covered from cardiac puncture from mice treated 346 
with ES (Center) and ES/ TRAIL liposomes (Right). (C) Number of viable cancer 347 
cells recovered per volume of mouse blood for mice treated with ES/TRAIL 348 
liposomes, soluble TRAIL (sTRAIL), ES liposomes, and buffer injections. n = 3 for 349 
all samples. Bars represent the mean ± SD in each treatment group. *P < 0.01, **P < 350 
0.001, ***P < 0.0001 (one-way ANOVA with Tukey posttest). (D) Representative 351 
micrographs of COLO 205 cells removed from circulation in mice treated with 352 
ES/TRAIL liposomes (Upper Left), sTRAIL (Upper Right), ES liposomes (Lower 353 
Left), and buffer (Lower Right) injections. (Scale bar, 20 μm.) (E) Leukocytes 354 
functionalized with fluorescent ES/TRAIL liposomes (green) upon removal from 355 
mouse circulation 2.5 h after injection. (Scale bar, 50 μm.)  356 
357 
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4.2.7 ES/TRAIL Treatment Reduces Number and Increases 358 
Apoptosis of Remaining Circulating COLO 205 Cells Lodged in Vivo 359 
in Mouse Lung.  360 
 361 
Previous studies have shown that tumor cells that enter the vasculature via tail- 362 
vein injection can lodge into lung vasculature within the first two hours (36). To assess 363 
the viability of the remaining circulating cancer cells lodged within mice, fluorescent 364 
COLO 205 cells lodged within the lungs of mice were identified using two-photon 365 
excited fluorescence microscopy (Fig. 6 A and B). Immediately following euthanasia, 366 
the lungs were resected, and two-photon images were acquired in three regions of the 367 
lung that were identical for each animal, to obtain an accurate estimate of cell counts 368 
(Fig. 6A). Roughly twice as many cells were found in the ES-, soluble TRAIL 369 
(sTRAIL), and buffer-treated animals as the ES/TRAIL-treated animals (Fig. 6C), 370 
suggesting that many COLO 205 cells had already died and degenerated. The cancer- 371 
cell density found in lung suggests that about 1.4 million cancer cells were lodged in 372 
the lung for buffer-treated animals (assuming a lung volume of ∼0.4 mL), representing 373 
the bulk of the two million COLO 205 cells injected.  374 
375 
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Figure 4.6 Decreased number and increased apoptosis in COLO 205 378 
cells lodged in mouse lung after treatment with ES/TRAIL liposomes.  379 
(A) Schematic of mouse lung and example two-photon excited fluorescence (2PEF) 380 
image stack from mouse lung where Hoechst-labeled COLO 205 cells (green) are 381 
arrested in lung tissue (visible by autofluorescence, yellow). (Scale bar, 80 μm.) (B) 382 
The 2PEF images of Hoescht-labeled COLO 205 cells (green) with Alexa Flour 568- 383 
labeled Annexin-V apoptosis probe (red) for each experimental group. Red arrows 384 
point to apoptotic COLO 205 cells (red and green colocalized), and blue arrows 385 
indicate nonapoptotic COLO 205 cells (green only). White circles indicate regions of 386 
autofluorescence from lung tissue. (Scale bar, 30 μm.) (C) Density of COLO 205 cells 387 
lodged in the lung for each experimental group. (D) Percentage of lodged COLO 205 388 
cells positive for Annexin-V probe for each experimental group. Individual data points 389 
represent data from one image stack, with points shown in the same color representing 390 
image stacks from the same animal. Superimposed box plots bound the 25th to 75th 391 
percentage of all data points and the whiskers extend 1.5 times the interquartile range 392 
beyond the boxes. The horizontal lines within the boxplot represent the median. n = 3 393 
animals for each experimental group. *P < 0.01, **P < 0.0001 (one-way ANOVA 394 
with Tukey posttest).  395 
396 
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We then evaluated the apoptotic effects of ES/TRAIL liposomes on cancer 397 
cells that have already lodged into the lungs of mice. After the injections of liposomes 398 
and COLO 205 at previously used time points (Fig. 5A), we injected a solution of 399 
Annexin-V tagged with a fluorescent Alexa 594 dye to assess for phosphatidylserine 400 
flipping on the COLO 205 cell membrane, characteristic of apoptosis. Mouse lungs 401 
were imaged using two-photon microscopy to determine whether Hoescht-labeled 402 
COLO 205 cells were also positive for Annexin-V labeling. In addition to the de- 403 
creased density of cancer cells lodged in mouse lung (Fig. 6C), we also found a 404 
dramatic increase in apoptosis of the cancer cells (Fig. 6 B and D) in the ES/TRAIL 405 
liposome-treated mice com- pared with other groups. Soluble TRAIL protein injected 406 
into mice following the same protocol displayed minimal cytotoxic activity 407 
comparable with control, as expected due to its short circulation half-life (37). Mice 408 
injected with ES/TRAIL liposomes survived for over 2 wk with no loss in body 409 
weight (n = 3). These data suggest that ES/TRAIL treatment serves to decrease the 410 
number of remaining circulating COLO 205 cells lodged in mouse lung, while 411 
increasing the fraction of them that are apoptotic.  412 
4.3 Discussion  413 
Natural killer cells, activated by interleukin-2 or other factors, are induced to 414 
present TRAIL protein on their surface. These cells participate in immunosurveillance 415 
against micrometastases in the body and comprise 10–20% of peripheral blood mono- 416 
nuclear cells (38, 39). Although the liposome-coated leukocytes described here are not 417 
specifically programmed to actively in- vade tissues and seek out solid tumors, they do 418 
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have frequent opportunities for incidental contact with CTCs in the blood- stream. 419 
Interestingly, infiltration of neutrophils and macro- phages throughout the interior of 420 
solid tumor masses has been found in dynamic, self-seeding tumors, suggesting that 421 
some degree of homing of normally functioning leukocytes to solid tumors could be 422 
expected (40, 41). We find that TRAIL is most potent when in its natural state— 423 
tethered to the surface of leukocytes in shear flow—rather than freely soluble or on 424 
untethered liposomes in the absence of blood. Tethering nanoscale liposomes to the 425 
surface of peripheral blood leukocytes is also beneficial for increasing liposome 426 
circulation time, by avoiding renal clearance mechanisms.  427 
So why do leukocytes coated with ES/TRAIL liposomes have much higher 428 
cytotoxic activity in shear flow, compared with isolated ES/TRAIL liposomes or 429 
soluble TRAIL protein? The answer may lie in the compressive force between 430 
surfaces. Two spherical particles colliding in linear shear flow will experience a 431 
compressive force between them, which scales as Fc ∼ µ*G*a*b, where µ is the fluid 432 
viscosity, G is the shear rate, and a and b are the radii of the smaller and larger sphere, 433 
respectively (42). Thus, a 10-µm-diameter leukocyte colliding with a cancer cell will 434 
experience 100 times the compressive force of a 100-nm liposome colliding with a 435 
cancer cell. Compressive forces act to flatten down any cell-surface glycocalyx 436 
composed of biologically inert macro- molecules, thus allowing TRAIL to come 437 
within a reactive distance to the cancer cell death receptors and form bonds. The 438 
physics of force-induced flattening and penetration of cell glycocalyx to facilitate 439 
surface receptor binding to ligands on an op- posing cell surface has been analyzed in 440 
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the context of leukocyte adhesion to the vascular endothelium (43, 44).  441 
Recombinant human TRAIL/Apo2L, also known as PRO1762 developed by 442 
Amgen/Genentech, has been the subject of numerous Phase 1, 1a, 2, and 3 clinical 443 
trials over the past decade, with minimal adverse effects reported (45, 46). There are 444 
many intracellular proteins, such as the inhibitors of apoptosis protein (IAPs) family 445 
members, that also confer TRAIL resistance to normal cells (47). Additionally, the 446 
dosages of TRAIL used in this current study ranged from 0.06–0.08 mg/kg, two orders 447 
of magnitude lower than the clinical dosages of 1–30 mg/kg used in human clinical 448 
trials. Although different types of cancer cells show different levels of sensitivity to 449 
TRAIL-induced apoptosis, it has been well documented that there is a wide range of 450 
agents known to sensitize cancer cells to TRAIL-mediated apoptosis, including 451 
conventional chemotherapeutics (camptothecin, cisplatin, doxorubicin, 5-fluorouracil, 452 
irinotecan, paclitaxel, gemcitabine), proteasome inhibitors, Bcl-2 inhibitors, IAP 453 
antagonists, histone deacetylase inhibitors, CD20 antibodies, irradiation, synthetic 454 
triterpenolds, Sorafenib, aspirin, and natural products such as curcumin and 455 
piperlongumine (48).  456 
What remains to be seen is whether ES/TRAIL liposomes can successfully 457 
prevent the formation of metastatic tumors; future work should focus on addressing 458 
this question. Additionally, human hepatocytes have shown sensitivity to TRAIL (49) 459 
although ES/TRAIL liposome adhesion to the leukocyte surface could reduce TRAIL 460 
uptake by the reticulo-endothelial system in the liver. The present study, however, 461 
represents an important first step toward the targeting of CTCs in the bloodstream as a 462 
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means to prevent cancer metastasis. Clinically, for instance, one could envision using 463 
these liposomes as a preventive mea- sure upon diagnosis of highly metastatic 464 
hematogenous cancers such as those originating in breast, prostate, and lung.  465 
4.4 Acknowledgements 466 
The authors thank Dr. Razelle Kurzrock for discussion on TRAIL toxicity, 467 
Julie Kohn and Brooke Mason of the Reinhart-King Lab for endothelial cell protocols, 468 
and Jeff Mattison for blood work. The work described was supported by the Cornell 469 
Center on the Microenvironment and Metastasis through Award U54CA143876 from 470 
the National Cancer Institute.  471 
 472 
4.5 References 473 
1. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. 474 
Science 331(6024):1559–1564.   475 
2. Riethdorf S, Wikman H, Pantel K (2008) Review: Biological relevance of 476 
disseminated tumor cells in cancer patients. Int J Cancer 123(9):1991–2006.   477 
3. Maheswaran S, Haber DA (2010) Circulating tumor cells: A window into 478 
cancer bi- ology and metastasis. Curr Opin Genet Dev 20(1):96–99.   479 
4. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 480 
420(6917):860–867.   481 
5. McDonald B, et al. (2009) Systemic inflammation increases cancer cell 482 
adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer 483 
125(6):1298–1305.   484 
6. van Ginhoven TM, van den Berg JW, Dik WA, Ijzermans JNM, de Bruin 485 
RWF (2010) Preoperative dietary restriction reduces hepatic tumor load by 486 
reduced E-selectin-  mediated adhesion in mice. J Surg Oncol 102(4):348–353. 487 
  488 
7. Gassmann P, Kang ML, Mees ST, Haier J (2010) In vivo tumor cell adhesion 489 
in the  pulmonary microvasculature is exclusively mediated by tumor cell— 490 
 62 
endothelial cell  interaction. BMC Cancer 10:177.   491 
8. Köhler S, Ullrich S, Richter U, Schumacher U (2010) E-/P-selectins and colon 492 
carcinoma  metastasis: First in vivo evidence for their crucial role in a 493 
clinically relevant model of  spontaneous metastasis formation in the lung. Br J 494 
Cancer 102(3):602–609.   495 
9. Rahn JJ, et al. (2005) MUC1 mediates transendothelial migration in vitro by 496 
ligating  endothelial cell ICAM-1. Clin Exp Metastasis 22(6):475–483.   497 
10. Chang YS, et al. (2000) Mosaic blood vessels in tumors: Frequency of cancer 498 
cells in  contact with flowing blood. Proc Natl Acad Sci USA 97(26):14608– 499 
14613.   500 
11. Butler TP, Gullino PM (1975) Quantitation of cell shedding into efferent blood 501 
of  mammary adenocarcinoma. Cancer Res 35(3):512–516.   502 
12. Allard WJ, et al. (2004) Tumor cells circulate in the peripheral blood of all 503 
major  carcinomas but not in healthy subjects or patients with nonmalignant 504 
diseases. Clin  Cancer Res 10(20):6897–6904.   505 
13. Yu M, Stott S, Toner M, Maheswaran S, Haber DA (2011) Circulating tumor 506 
cells:  Approaches to isolation and characterization. J Cell Biol 192(3):373– 507 
382.   508 
14. Firrell JC, Lipowsky HH (1989) Leukocyte margination and deformation in 509 
mesenteric  venules of rat. Am J Physiol 256(6 Pt 2):H1667–H1674.   510 
15. Läubli H, Borsig L (2010) Selectins promote tumor metastasis. Semin Cancer 511 
Biol 20(3):  169–177.   512 
16. Gout S, Tremblay PL, Huot J (2008) Selectins and selectin ligands in 513 
extravasation of  cancer cells and organ selectivity of metastasis. Clin Exp 514 
Metastasis 25(4):335–344.   515 
17. Barthel SR, et al. (2009) Alpha 1,3 fucosyltransferases are master regulators of 516 
prostate cancer cell trafficking. Proc Natl Acad Sci USA 106(46):19491– 517 
19496.  518 
18. Ashkenazi A, Holland P, Eckhardt SG (2008) Ligand-based targeting of 519 
apoptosis in cancer: the potential of recombinant human apoptosis ligand 520 
2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). 521 
J Clin Oncol 26(21):3621–3630.   522 
19. Walczak H, et al. (1999) Tumoricidal activity of tumor necrosis factor-related 523 
apo-  ptosis-inducing ligand in vivo. Nat Med 5(2):157–163.   524 
20. Kim MB, Sarelius IH (2003) Distributions of wall shear stress in venular 525 
convergences  of mouse cremaster muscle. Microcirculation 10(2):167–178.   526 
21. Mitchell MJ, King MR (2013) Computational and experimental models of 527 
 63 
cancer cell  response to fluid shear stress. Front Oncol 3:44.   528 
22. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte 529 
emigration: the multistep paradigm. Cell 76(2):301–314.   530 
23. Doherty TA, et al. (2012) STAT6 regulates natural helper cell proliferation 531 
during lung  inflammation initiated by Alternaria. Am J Physiol Lung Cell Mol 532 
Physiol 303(7):L577–L588.   533 
24. Malý P, et al. (1996) The alpha(1,3)fucosyltransferase Fuc-TVII controls 534 
leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand 535 
biosynthesis. Cell  86(4):643–653.   536 
25. Janssen EM, et al. (2005) CD4+ T-cell help controls CD8+ T-cell memory via 537 
TRAIL-  mediated activation-induced cell death. Nature 434(7029):88–93.   538 
26. Goldsmith HL (1968) The microrheology of red blood cell suspensions. J Gen 539 
Physiol 52(1):5–28.  540 
27. Goldsmith HL, Bell DN, Braovac S, Steinberg A, McIntosh F (1995) Physical 541 
and chemical effects of red cells in the shear-induced aggregation of human 542 
platelets. Biophys J 69(4):1584–1595.  543 
28. Yan L, Cai Q, Xu Y (2013) The ubiquitin-CXCR4 axis plays an important role 544 
in acute lung infection-enhanced lung tumor metastasis. Clin Cancer Res 545 
19(17):4706–4716.  546 
29. Tucci P, et al. (2012) Loss of p63 and its microRNA-205 target results in 547 
enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci 548 
USA 109(38):15312–15317.  549 
30. Chang C-Y, Lin S-C, Su W-H, Ho C-M, Jou Y-S (2012) Somatic LMCD1 550 
mutations pro- moted cell migration and tumor metastasis in hepatocellular 551 
carcinoma. Oncogene 31(21):2640–2652.  552 
31. Kim S, et al. (2009) Carcinoma-produced factors activate myeloid cells 553 
through TLR2 to stimulate metastasis. Nature 457(7225):102–106.  554 
32. Fidler IJ (1975) Biological behavior of malignant melanoma cells correlated to 555 
their survival in vivo. Cancer Res 35(1):218–224. 33.  556 
33. Fidler IJ (1974) Inhibition of pulmonary metastasis by intravenous injection of 557 
specifically activated macrophages. Cancer Res 34(5):1074–1078.  558 
34. Fidler IJ, Nicolson GL (1976) Organ selectivity for implantation survival and 559 
growth of B16 melanoma variant tumor lines. J Natl Cancer Inst 57(5):1199– 560 
1202. 561 
35. Kato N, et al. (2009) The E-selectin ligand basigin/CD147 is responsible for 562 
neutrophil recruitment in renal ischemia/reperfusion. J Am Soc Nephrol 563 
20(7):1565–1576.  564 
36. Fidler IJ, Nicolson GL (1977) Fate of recirculating B16 melanoma metastatic 565 
variant cells in parabiotic syngeneic recipients. J Natl Cancer Inst 58(6):1867– 566 
1872.  567 
37. Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandón E (2004) Tissue 568 
distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis 569 
factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 570 
 64 
tumor-bearing nude mice.  571 
38. Drug Metab Dispos 32(11):1230–1238. 38. Takeda K, et al. (2005) TRAIL 572 
identifies immature natural killer cells in newborn mice and adult mouse liver. 573 
Blood 105(5):2082–2089.  574 
39. Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. 575 
Oncogene 27(45):5932–5943.  576 
40. Kim MY, et al. (2009) Tumor self-seeding by circulating cancer cells. Cell 577 
139(7):1315–1326.  578 
41. Bernal M, et al. (2011) Leukocyte infiltrate in gastrointestinal 579 
adenocarcinomas is strongly associated with tumor microsatellite instability 580 
but not with tumor immunogenicity. Cancer Immunol Immunother 60(6):869– 581 
882.  582 
 583 
42. Shankaran H, Neelamgham S (2004) Hydrodynamic forces applied on 584 
intercellular bonds, soluble molecules, and cell-surface receptors. Biophys J 585 
86(1 Pt 1):576–588.  586 
43. Zhao Y, Chien S, Weinbaum S (2001) Dynamic contact forces on leukocyte 587 
microvilli and their penetration of the endothelial glycocalyx. Biophys J 588 
80(3):1124–1140.  589 
44. Sabri S, et al. (2000) Glycocalyx modulation is a physiological means of 590 
regulating cell adhesion. J Cell Sci 113(Pt 9):1589–1600.  591 
45. Subbiah V, et al. (2012) Targeting the apoptotic pathway in chondrosarcoma 592 
using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic 593 
receptor (DR4/ DR5) agonist. Mol Cancer Ther 11(11):2541–2546.  594 
46. Herbst RS, et al. (2010) Phase I dose-escalation study of recombinant human 595 
Apo2L/ TRAIL, a dual proapoptotic receptor agonist, in patients with 596 
advanced cancer. J Clin Oncol 28(17):2839–2846.  597 
47. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P (2000) Mechanisms 598 
of resistance of normal cells to TRAIL induced apoptosis vary between 599 
different cell types. FEBS Lett 482(3):193–199.  600 
48. Ashkenazi A, Herbst RS (2008) To kill a tumor cell: The potential of 601 
proapoptotic  602 
49. receptor agonists. J Clin Invest 118(6):1979–1990.  603 
50. Jo M, et al. (2000) Apoptosis induced in normal human hepatocytes by tumor 604 
necrosis factor-related apoptosis-inducing ligand. Nat Med 6(5):564–567.  605 
 606 
 607 
 608 
 609 
610 
 65 
4.6 Supplemental Information Materials and Methods  611 
Reagents and Antibodies 612 
Human serum albumin (HSA), BSA, Accutase, Hepes, DMSO, NaCl, MgCl2, 613 
CaCO3 and chloroform (ACS grade with 0.5–1% ethanol added as stabilizer) were all 614 
obtained from Sigma-Aldrich. RPMI 1640 cell culture media, FBS, HBSS, penicillin- 615 
streptomycin (PenStrep), and Dulbecco’s PBS (DPBS) were all obtained from 616 
Invitrogen. His-tagged re- combinant human tumor necrosis factor-related apoptosis- 617 
inducing ligand (TRAIL), his-tagged recombinant human E-selectin-IgG chimera 618 
(ES), and Annexin-V FITC Apoptosis Detection Kit were purchased from R&D 619 
Systems. 2′,7′-bis-(2-carboxyethyl)- 5-(and-6)-carboxyfluorescein, acetoxymethyl 620 
ester solution and trypsin-EDTA solution were obtained from Invitrogen. PBS- based 621 
enzyme-free cell dissociation media was purchased from Millipore. L-α- 622 
lysophosphatidylcholine from egg (Egg PC), sphin- gomyelin from egg (Egg SM), 623 
ovine wool cholesterol (Chol), 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1- 624 
carboxypentyl) imino- diacetic acid) succinyl] (nickel salt) (DOGS-Ni-NTA), and 23- 625 
(dipyrrometheneboron difluoride)-24-norcholesterol (Bdp-Chol, Ex/Em 490 nm/504 626 
nm) either dissolved in chloroform (Egg PC, Egg SM, Chol, DOGS NTA-Ni) or in 627 
powder form (Bdp-Chol) were purchased from Avanti Polar Lipids. Rat anti-human 628 
CD62E (E-selectin) antibody was purchased from Abcam. Anti- human CD3, CD14, 629 
CD16, CD19, and CD56 conjugated with Pacific Blue, APC Cy7, PERCP-Cy5.5, 630 
APC, and PE, respectively, along with corresponding isotypes were all purchased 631 
from BD Biosciences.  632 
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Cell Lines and Cell Culture 633 
Colon cancer cell line COLO 205 (ATCC number CCL-222) was obtained 634 
from ATCC and cul- tured in RPMI 1640 supplemented with 2 mM L-Glutamine, 25 635 
mM Hepes, 10% (vol/vol) FBS and 100 U/mL PenStrep (com- plete media) under 636 
humidified conditions at 37 °C and 5% CO2. Prostate cancer cell line PC-3 (ATCC 637 
number CRL-1435) was obtained from ATCC and cultured in F-12K medium supple- 638 
mented with 10% (vol/vol) FBS and 100 U/mL PenStrep. Hu- man umbilical vein 639 
endothelial cells (HUVECs) were purchased from Cascade Biologics and maintained 640 
in Medium 200 (Cas- cade Biologics) supplemented with low-serum growth supple- 641 
ment (Cascade Biologics) and 5% FBS (Invitrogen). HUVECs from passages 2–5 642 
were used for experiments. For all experi- ments, >95% viability was assessed by 643 
trypan blue exclusion dye.  644 
 645 
Preparation of Liposomes 646 
Multilamellar liposomes, composed of egg L-α-lysophosphatidylcholine (Egg 647 
PC), egg sphingomyelin (Egg SM), ovine wool cholesterol (Chol), and 1,2-dioleoyl- 648 
sn-glyc- ero-3-[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl] (nickel 649 
salt) (DOGS NTA-Ni) at weight ratios 60–50%:30%:10%:0– 10% (Egg PC/Egg 650 
SM/Chol/DOGS NTA-Ni), were prepared using a thin lipid film method. DOGS- 651 
NTA-Ni is a lipid conjugated to nickel-nitrilotriacetic acid (Ni-NTA) that allows for 652 
attachment to his-tagged proteins. Briefly, stock solutions of all lipids were pre- pared 653 
by dissolving powdered lipids in chloroform to produce a final concentration of 5 654 
mg/mL Egg PC, 20 mg/mL Egg SM, 5 mg/mL Chol, and 20 mg/mL DOGS-NTA-Ni 655 
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in glass containers and stored at −20 °C. Appropriate volumes of the lipids were taken 656 
from the stock solution to make lipids with varying concentrations of DOGS NTA-Ni 657 
in a glass tube and gently dried under nitrogen. To ensure complete removal of 658 
chloroform, the lipids were left under vacuum for an additional 12 h. With increasing 659 
amounts of DOGS NTA-Ni, the corresponding amount of Egg PC was decreased 660 
(Table S1). The lipid film was hydrated with a liposome buffer composed of 150 mM  661 
NaCl, 10 mM Hepes, and 1 mM MgCl2 dissolved in nuclease-free water to 662 
create multilamellar liposomes. The resulting multi- lamellar liposomes were sized by 663 
repeated thawing and freezing, and then subjected to 15 extrusion cycles at 60 °C 664 
through two different pore size (200 and 100 nm) polycarbonate membranes 665 
(Nucleopore; Whatman) to produce unilamellar nanoscale lip- osomes. Recombinant 666 
human ES and TRAIL were dissolved in nuclease-free sterile water to a final 667 
concentration of 1 mg/mL, and 100 µg/mL aliquots of stock solutions were stored at – 668 
20 °C and used as needed within 60 d. Freshly prepared nanoscale liposomes were 669 
then incubated with ES (final concentration 71.43 nM) and TRAIL (250 nM final 670 
concentration) for 30 min at 37 °C and then overnight at 4 °C, to ensure maximum 671 
protein binding via the interaction between his-tag and Ni-NTA. Based on 672 
approximations for ligand density on liposomes suggested in previous work by Huang 673 
and Mason (1), there were ∼65 TRAIL and 19 E-selectin proteins present on the 674 
surface of each li- posome, assuming a unilamellar liposome diameter of 100 nm. To 675 
remove unbound TRAIL and ES, liposomes were diluted 1:6 with liposome buffer and 676 
subjected to ultracentrifugation at 100,000 × g for 3 h at 4 °C. The supernatant with 677 
unbound TRAIL and ES was carefully removed and collected for further evaluation, 678 
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and the remaining liposomes were gently resuspended in buffer. A similar procedure 679 
was used to create fluorescent conjugated liposomes by replacing ovine wool 680 
cholesterol with 23- (dipyrrometheneboron difluoride)-24-norcholesterol. Freshly pre- 681 
pared nanoscale liposomes were diluted in buffer, and the mean particle diameter and 682 
surface charge (zeta potential) were mea- sured by dynamic light scattering using a 683 
Malvern Zetasizer nano ZS (Malvern Instruments Ltd.), according to the 684 
manufacturer’s protocols. Conjugated liposomes were measured to be 117.8 ± 10.3 nm 685 
in diameter, with a zeta potential of −5.7 ± 4.6 mV.  686 
Static Experiments 687 
COLO 205 cells were seeded in multiwell plates at a seeding density of 688 
300,000 cells per mL, 1 d before experimentation to ensure that the cells were in the 689 
linear phase of the growth cycle. Media was changed before experimentation. Cells 690 
were incubated with either the supernatant from ultra- centrifugation or 10 µL of 691 
conjugated and purified liposomes. The cells were maintained in culture conditions 692 
with the super- natant or nanoscale lipids for 24 h and later analyzed by an Annexin-V 693 
assay to quantify the proportion of viable cells.  694 
 695 
Uniform Shear-Flow Experiments  696 
To simulate the shear-stress conditions of blood flow, cancer cells were 697 
subjected to uniform shear in a cone-and-plate viscometer (2, 3). Cancer cells seeded 1 698 
d before the experiment were gently detached from the surface using PBS-based 699 
enzyme-free cell-detachment solution or accutase. Cells were then washed twice in 1× 700 
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DPBS and resuspended in buffer at a concentration of 1 × 106 cells per mL. Then, 10 701 
µL of lipids was added to 490 µL of cell suspension (at 106 cells per mL) and 702 
immediately added to the cone-and-plate viscometer. Cell suspensions were exposed 703 
to shear flow at a shear rate of 188 s−1 for 2 h. All samples were exposed to shear 704 
flow at room temperature to prevent potential sample evaporation and/or drying in the 705 
cone-and-plate viscometer over prolonged periods of shear. After 2 h, the cells were 706 
removed and washed twice in resuspension buffer at 200 × g for 5 min. Cells were 707 
resuspended in complete media and cultured for 24 h. In the case of fluo- rescent 708 
lipids, an aliquot was taken for visual inspection on an inverted microscope (Olympus 709 
America Inc.) equipped with fluorescence and an intensified CCD digital camera 710 
(Cooke Corporation) to record images. For spiking experiments, periph- eral blood 711 
was collected into Vacutainer tubes containing heparin and allowed to equilibrate to 712 
room temperature before use. Then, 1 × 106 COLO 205 or PC-3 cells were tagged 713 
fluorescently with 3 µM BCECF AM solution for 15 min at 37 °C, washed twice, and 714 
collected via centrifugation at 200 × g for 5 min. The supernatant was discarded, and 715 
the collected cells were re- suspended in 1 mL of whole blood. Then, 10 µL of lipid 716 
was then added to 490 µL of spiked blood and immediately added to a cone-and-plate 717 
viscometer previously coated with 5% BSA. Spiked blood was subjected to a uniform 718 
shear rate of 188 s−1 for 2 h. As an additional comparison for spiking experiments, 719 
identical experiments were performed in buffer instead of whole blood. In leukocyte 720 
functionalization experiments, 10 µL of lipid was added to 490 µL of human blood, 721 
sheared in a cone-and-plate viscometer at a uniform shear rate of 188 s−1 for 2 h, and 722 
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sub- sequently centrifuged to remove the plasma containing unbound liposomes. The 723 
removed plasma was replaced with freshly isolated plasma, and the blood samples 724 
were used for identical spiking experiments mentioned above. After shearing, the 725 
blood sample was collected from the device and carefully layered over 1.5 mL of 726 
Ficoll and centrifuged at 480 × g for 50 min at room temperature. The buffy coat 727 
containing mononuclear cells (MNCs) and cancer cells was recovered and washed 728 
twice in resuspension buffer, col- lected, cultured for 24 h, and analyzed for viable 729 
fluorescent cancer cells using flow cytometry. To evaluate the effect of hematocrit, the 730 
number of RBCs was varied by removal via centrifugation. Vol- umes of RBCs were 731 
replaced with excess plasma from the same blood donor. Cancer cells were spiked into 732 
blood samples as mentioned earlier, at a concentration of 1 × 106 cells per mL. Then, 733 
10 µL of liposome solution was added to 490 µL of blood and sheared for 2 h at 188 734 
s−1. Samples were collected, incubated, and analyzed for viability on a flow 735 
cytometer as described in Flow Cytometry. In some experiments, 490 µL of whole 736 
blood was sheared with 10 µL of liposome solution, and the plasma and any remaining 737 
unbound liposomes and/or liposome fragments were separated by centrifugation. To 738 
determine the effects of remaining unbound liposomes and/or liposome fragments on 739 
cancer-cell vi- ability, the recovered plasma was incubated with 500,000 COLO 205 740 
cells for 24 h at 37 °C and analyzed for cell viability using flow cytometry.  741 
Polymorphonuclear and Mononuclear Cell Isolation 742 
All human subject protocols were approved by the Institutional Review Board 743 
for Human Participants of Cornell University. Peripheral blood was collected from 744 
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healthy donors after informed consent into Vacutainer tubes containing heparin and 745 
allowed to equil- ibrate at room temperature before use (2, 4). Then, 3 mL of blood 746 
diluted with resuspension buffer was carefully layered over 3 mL of 1-Step 747 
Polymorphs (Accurate Chemical & Scientific Corporation) and centrifuged at 480 × g 748 
for 50 min at room temperature. Two separate layers of MNCs and polymorpho- 749 
nuclear cells (PMNs) were collected and washed twice with re- suspension buffer.  750 
Leukocyte Functionalization with ES/TRAIL Liposomes in Whole 751 
Blood.  752 
To assess the adhesion of ES/TRAIL liposomes to leukocytes in whole blood 753 
under flow, 490 µL of whole blood was sheared with 10 µL of fluorescent ES/TRAIL 754 
liposome solution for 30 min in a cone-and-plate viscometer at a shear rate of 188 s−1. 755 
Leuko- cytes were then separated using 1-Step Polymorphs and assessed for adherent 756 
ES/TRAIL liposomes using confocal microscopy. To assess the fraction of leukocyte 757 
subpopulations that adhere to ES/TRAIL liposomes, leukocytes were labeled with 758 
anti-human CD3, CD14, CD16, CD19, and CD56, along with corresponding isotype 759 
controls, and analyzed for adherent ES/TRAIL liposomes using flow cytometry. To 760 
assess the specificity of the ES interaction with leukocytes, liposomes were incubated 761 
with a functional blocking anti-human E-selectin antibody before shearing in whole 762 
blood. To assess the fraction of leukocytes in blood ad- hered to ES/TRAIL liposomes 763 
before shear, fluorescent ES/ TRAIL liposomes were added to whole blood and then 764 
sepa- rated using 1-Step Polymorphs.  765 
Endothelial-Cell Viability Assay  766 
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Forty-millimeter-diameter circular glass coverslips (Thermo Scientific) were 767 
plasma-treated (Harrick Plasma Cleaner) for 2 min and subsequently incubated in 1% 768 
polyethylenemine (PEI) at room temperature for 10 min. Cov- erslips were then 769 
washed in water three times and treated with 0.1% glutaraldehyde (Sigma-Aldrich) in 770 
PBS at room tempera- ture for 30 min. Coverslips were washed in water three times, 771 
dried, and treated with 0.1 mg/mL type I rat-tail collagen (Becton Dickinson) in Hepes 772 
(pH 8.0; Sigma-Aldrich) for 2 h at 4 °C. Coverslips were placed in Petri dishes (60 773 
mm × 15 mm; Sigma- Aldrich), washed three times in PBS, and briefly sterilized via 774 
UV exposure for 15 min. HUVECs were plated on coverslips, at a density of 500,000 775 
cells per coverslip, in Medium 200 supple- mented with low-serum growth 776 
supplement (Cascade Biologics), 5% FBS (Invitrogen), and 100 U/mL PenStrep. 777 
HUVECs were cultured for 4 d on coverslips before experiments and then ad- hered to 778 
the plate of a cone-and-plate viscometer using vacuum grease. HUVECs were then 779 
treated with 2.94 mL of human blood and 60 µL of PBS, ES/TRAIL (TRAIL final 780 
concentra- tion: 0.3 µg/mL), or soluble TRAIL in PBS (TRAIL final con- centration: 781 
0.3 µg/mL) for 4 h at 37 °C in a humidified cone-and- plate viscometer at a shear rate 782 
of 188 s−1. As a positive control, HUVECs were treated with a high concentration of 783 
soluble TRAIL (15 µg/mL). Coverslips were removed from the viscom- eter, gently 784 
washed in PBS, and placed in Medium 200 supple- mented with low-serum growth 785 
supplement, 5% FBS (Invitrogen), and 100 U/mL PenStrep. HUVEC morphology was 786 
assessed using brightfield and phase-contrast microscopy. HUVECs were im- 787 
mediately placed into culture for 8 h, maintained at 37 °C and 5% CO2. HUVECs 788 
were then treated with 0.25% Trypsin-EDTA solution (Gibco) for 2 min at 37 °C, 789 
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followed by treatment with an equal volume of trypsin neutralizer solution (Gibco). 790 
HUVECs were collected from coverslips, washed twice in PBS, and assessed for 791 
viability using an Annexin-V assay.  792 
Liposome and COLO 205 Cell Injection in Mice 793 
C57BL/6J mice aged 16–20 wk (both sexes), weighing 25–32 g, were obtained 794 
from The Jackson Laboratory. Mice were anesthetized using iso- flurane (5%) for all 795 
procedures. Either 120 µL of saline, sTRAIL (15 µg/mL; TRAIL plasma concentration 796 
∼1.0 µg/mL), ES/ TRAIL (TRAIL injection concentration 15 µg/mL; TRAIL plasma 797 
concentration ∼1.0 µg/mL) liposomes, or ES liposomes suspended in saline were 798 
injected retro-orbitally using a 30-G needle, and animals were removed from 799 
anesthesia. Three mice were used in each group. Thirty minutes later, animals were 800 
reanesthetized, and ∼2 × 106 COLO 205 cells, labeled by 2 µg/ mL Hoescht (H1399; 801 
Invitrogen) or 3 µM BCECF AM sus- pended in saline were injected into the tail vein. 802 
Animals were removed from anesthesia, and the cancer cells were allowed to circulate 803 
for 2 h. All animal procedures were approved by the Cornell University Institutional 804 
Animal Care and Use Committee.  805 
Analysis of Circulating COLO 205 Cells  806 
Animals were euthanized with a lethal dose of pentobarbital. Blood was 807 
removed from the heart via cardiac puncture and collected into sodium heparin- coated 808 
tubes. Leukocytes and circulating COLO 205 cells were separated using Ficoll-Paque 809 
PLUS. After centrifugation, the MNC buffy coat was collected, washed in buffer 810 
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containing Ca2+ and cultured for 2–3 h in multiwell plates. Cell viability was as- 811 
sessed using flow cytometry.  812 
Two-Photon Imaging of Lung Tissue 813 
Animals were anesthetized and received injections of saline, sTRAIL, 814 
ES/TRAIL liposomes, or ES liposomes, followed by an injection of Hoescht-labeled 815 
cancer cells, as described in Liposome and COLO 205 Cell Injection in Mice. After 2 816 
h of cancer-cell circulation, an Alexa Fluor 568- labeled Annexin-V probe (A13202; 817 
Invitrogen) was injected retro- orbitally and allowed to circulate for 2 h to ensure 818 
maximum detection of apoptotic cells. Animals were then given a lethal dose of 819 
pentobarbital. After euthanasia, intact lungs were re- sected and immediately imaged 820 
via two-photon excited fluores- cence microscopy. Two-photon imaging was 821 
conducted on a locally designed microscope using a train of 800-nm, 87- MHz, 100-fs 822 
pulses from a Ti:sapphire laser oscillator (MIRA HP, pumped by a Verdi-V18; 823 
Coherent) for excitation. Laser scanning and data acquisition were controlled by 824 
ScanImage software. For high-resolution imaging of COLO 205 Hoechst- labeled 825 
nuclei and Annexin V labeling, a 20× (numerical ap- erture: 0.95) water-immersion 826 
objective (Olympus) was used. Fluorescence was detected using emission filters with 827 
460-nm and 645-nm center wavelength with 65-nm bandwidth to image Hoescht and 828 
Alexa Fluor 568 (Invitrogen), respectively. Spec- trally broad autofluorescence from 829 
the lung tissue was visible in both channels.  830 
Counting and Viability Scoring of COLO 205 Cells in Lung 831 
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Hoechst- labeled COLO 205 cells were manually counted from ∼10 rep- 832 
resentative two-photon image stacks taken from the lung in each mouse using Image J 833 
(NIH) cell counting software. The Hoechst signal was of similar magnitude to the 834 
background lung auto- fluorescence in the 460-nm channel. To aid in identifying 835 
nuclei, the Hoechst channel was compared with the 645-nm channel, where 836 
autofluorescence was also visible, but Hoescht was not and Alexa Fluor 568 signal 837 
was significantly brighter than au- tofluorescence. In addition, attributes such as size 838 
and shape to distinguish the labeled COLO 205 cells were used. Each imaged volume 839 
was about 0.022 mm3. The total number of cells in the lung was estimated by scaling 840 
the imaged volumes to the total lung volume, which was measured via a volume- 841 
displacement method. Counts were recorded by two different observers, each blinded 842 
to the treatment received, and averaged. To determine which COLO 205 cells were 843 
apoptotic, we determined whether Alexa Fluor 568 Annexin V labeling was present at 844 
each of the COLO 205 cell nuclei we identified.  845 
Flow Cytometry  846 
Mode of cell death was analyzed using an Annexin-V apoptosis assay on an 847 
Accuri C6 flow cytometer. Samples were prepared per the manufacturer’s instructions. 848 
Briefly, cells were classified into four categories based on dye uptake: viable cells 849 
[negative for Annexin-V and propidium iodide (PI)], early apo- ptotic cells (positive 850 
for Annexin-V only), late apoptotic cells (positive for Annexin-V and PI), and necrotic 851 
cells (positive for PI only). For blood spiking experiments, fluorescent untreated 852 
cancer cells and liposome-treated samples were assessed for viability us- ing a flow 853 
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cytometer. A gate was set based on a viable, untreated cancer-cell control. Equal 854 
volumes from all samples were used for analysis. Cell viability was determined by 855 
measuring the amount of cells positive for fluorescent BCECF staining. For in vivo 856 
animal experiments, 100 µL of each sample was processed. A gate de- noting viable, 857 
BCECF AM-labeled cancer cells was established by processing a viable, fluorescent 858 
sample of COLO 205 cells in buffer. COLO 205 cells recovered from mouse blood 859 
were differentiated based on size and fluorescence using flow cytometry. The number 860 
of cancer cells per milliliter of mouse blood was determined based on the amount of 861 
mouse blood recovered from each animal.  862 
Statistical Analysis  863 
Where appropriate, Student t test and one-way ANOVA with Tukey posttest 864 
comparing all means were used at a significance level of α = 0.05. All statistical 865 
analyses were performed using GraphPad Prism 5.0c for Mac OS X (GraphPad 866 
software) and Kaleidagraph (Synergy) software.  867 
4.7 Supplementary Results 868 
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 869 
Sup Fig 4.1 Incorporation of Ni-NTA–conjugated lipids on liposomes maximizes 870 
protein conjugation to the liposome surface. To determine the optimal amount Ni- 871 
NTA-conjugated lipid required to bind TRAIL and ES to the liposome surface, COLO 872 
205 cells were incubated with supernatant left after liposome prep- aration and 873 
assayed for cell viability. Increased cell death is indicative of more unbound TRAIL 874 
protein in solution. (A–D) Annexin-V apoptosis assay of COLO 205 cell viability 875 
after incubation with supernatant of liposomes conjugated to 0% (A), 1% (B), 5% (C), 876 
and 10% Ni-NTA (D) postultracentrifugation, with varying amounts of Ni-NTA 877 
conjugated to the liposome surface. Cells were classified into four categories based on 878 
dye uptake: viable cells (negative for Annexin-V and PI), early apoptotic cells 879 
(positive for Annexin-V only), late apoptotic cells (positive for Annexin-V and PI), 880 
and necrotic cells (positive for PI only). (E) COLO 205 cell viability after treatment 881 
with unbound TRAIL and ES in liposome supernatant. n = 3 for all samples. Bars 882 
represent the mean ± SD in each treatment group. (F) Representative micrographs of 883 
untreated COLO 205 cells (Top) and those treated with the supernatant of liposomes 884 
conjugated to 0% (Middle) and 10% Ni-NTA (Bottom). The 10% Ni-NTA– 885 
conjugated lipid on the liposome leads to nearly complete incorporation of TRAIL and 886 
ES onto the liposome surface. (Scale bar, 50 μm.)  887 
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 890 
Sup Fig 4.2 ES/TRAIL liposomes are somewhat effective in targeting and killing 891 
COLO 205 cells under static conditions. (A–D) Annexin-V apoptosis plots of 892 
COLO 205 cells treated with ES/TRAIL liposomes consisting of 0% (A), 1% (B), 5% 893 
(C), and 10% Ni-NTA (D) for 24 h. (E) Representative micrographs showing COLO 894 
205 cells after 24 h incubation with liposomes. (Scale bar, 50 μm.) (F) COLO 205 cell 895 
viability following incubation with liposomes with varying amounts of Ni-NTA on the 896 
liposome surface. n = 3 for all samples. Bars represent the mean ± SEM in each 897 
treatment group.  898 
 899 
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Sup Fig 4.3 ES/TRAIL liposomes adhesively interact with cancer cells. (A) Flow- 901 
cytometry plots of cancer cells positive for fluorescently tagged ES/TRAIL liposomes 902 
(green). Gray population represents fluorescence of COLO 205 cells in the absence of 903 
fluorescent ES/TRAIL liposomes. (B) Percent of COLO 205 cells adhered to 904 
liposomes following shear flow at a shear rate of 188s−1. n = 3 for all samples. Bars 905 
represent the mean ± SEM in each treatment group. (C and D) Repre- sentative 906 
fluorescent (C) and brightfield (D) micrographs of COLO 205 cells adhered to 907 
fluorescently tagged liposomes following shear flow. (Scale bar, 20 μm.)  908 
 909 
 910 
 911 
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913 
Sup Fig 4.4. Leukocyte functionalization with ES/TRAIL does not induce 914 
significant leukocyte death. (A–C) Representative propidium iodide/Annexin-V 915 
flow- cytometry plots of untreated mononuclear cells (A) and those treated with ES 916 
(B) and ES/TRAIL (C) liposomes under static conditions for 24 h. (D) Viability of 917 
mononuclear cells following incubation with liposomes for 24 h. n = 3 for all samples. 918 
Bars represent the mean ± SEM in each treatment group. NS, not significant (one-way 919 
ANOVA with Tukey posttest). (E–G) Representative propidium iodide/Annexin-V 920 
flow-cytometry plots of untreated mononuclear cells (E) and those treated with ES (F) 921 
and ES/TRAIL (G) liposomes under shear flow (shear rate: 188 s−1) for 2 h. (H) 922 
Viability of MNCs treated with liposomes under shear flow for 2 h. n = 3 for all 923 
samples. Bars represent the mean ± SD in each treatment group. NS, not significant 924 
(one-way ANOVA with Tukey posttest).  925 
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 926 
Sup Fig 4.5 Leukocyte functionalization with ES/TRAIL does not induce 927 
significant endothelial cell death. (A) Representative images of HUVECs 928 
immobilized on coverslips immediately after treatment in human blood, with various 929 
drug treatments, under shear flow (shear rate: 188 s−1) for 4 h at 37 °C. (Scale bar, 930 
100 μm.) (B–D) Representative propidium iodide/Annexin-V flow cytometry plots of 931 
untreated HUVECs (B) and those treated with ES/TRAIL liposomes (C) (TRAIL 932 
concentration 0.3 μg/mL) or soluble TRAIL (D) (TRAIL concentration 0.3 μg/mL) in 933 
human blood under shear flow for 4 h at 37 °C. (E) As a positive control, HUVECs 934 
were treated with a high dosage of TRAIL (15 μg/mL) in human blood under shear 935 
flow for 4 h at 37 °C. HUVECs were classified into four categories based on dye 936 
uptake: viable cells (negative for Annexin-V and PI), early apoptotic cells (positive for 937 
Annexin-V only), late apoptotic cells (positive for Annexin-V and PI), and necrotic 938 
cells (positive for PI only). (F) Percent viability of HUVECs after various drug 939 
treatments in human blood under shear flow for 4 h at 37 °C. n = 3 for all samples. 940 
Bars represent the mean ± SD in each treatment group. **P <0.001. NS, not 941 
significant (one-way ANOVA with Tukey posttest).  942 
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 947 
Sup Fig 4.6 Low toxicity of blood plasma after treatment with ES/TRAIL 948 
liposomes. (A) Viability of COLO 205 cells after treatment with plasma from normal 949 
healthy blood for 24 h. (B) Viability of COLO 205 cells after treatment with plasma 950 
extracted from blood that had been sheared with ES/TRAIL liposomes for 30 min. 951 
Cells were incubated with plasma, and any remaining unbound ES/TRAIL liposomes 952 
and/or liposome fragments in the plasma for 24 h, and analyzed for cell viability.  953 
954 
 83 
 955 
 956 
 957 
 958 
 959 
 960 
961 
 84 
 962 
4.8 References 963 
1. Huang C, Mason JT (1978) Geometric packing constraints in egg 964 
phosphatidylcholine vesicles. Proc Natl Acad Sci USA 75(1):308–310.  965 
2. Mitchell MJ, King MR (2012) Shear-induced resistance to neutrophil activation via 966 
the formyl peptide receptor. Biophys J 102(8):1804–1814.  967 
3. Mitchell MJ, King MR (2013) Fluid shear stress sensitizes cancer cells to receptor- 968 
mediated apoptosis via trimeric death receptors. New J Phys 15:015008.  969 
4. Ball CJ, King MR (2011) Role of c-Abl in L-selectin shedding from the neutrophil 970 
surface. Blood Cells Mol Dis 46(3):246–251.  971 
 972 
 973 
 85 
CHAPTER 5 1 
ES/TRAIL COATED LEUKOCYTES ELIMINATE METASTASIS BY 2 
TARGETING AND KILLING CIRCULTING TUMOR CELLS IN AN 3 
ORTHOTOPIC PROSTATE TUMOR MODEL 4 
 5 
 6 
 7 
 8 
 9 
 10 
In this chapter, we present a study that investigates the use of ES/TRAIL coated 11 
leukocytes to kill circulating tumor cells (CTCs) and reduce metastasis in an 12 
orthotopic prostate tumor model. For the first time, it is shown that such an approach 13 
can be used to prevent the spontaneous formation and growth of metastatic tumors in 14 
an orthotopic xenograft model of prostate cancer, by greatly reducing the number of 15 
circulating tumor cells. We conclude that the use of circulating leukocytes as a carrier 16 
for the anti-cancer protein TRAIL could be an effective tool to directly target 17 
circulating tumor cells for the prevention of prostate cancer metastasis, and potentially 18 
other cancers that spread through the bloodstream. 19 
 20 
At the time of the writing of this dissertation, this work is currently under review in 21 
the Proceedings of the National Academy of the Sciences. The manuscript cwill 22 
eventually have the following citation:  23 
 24 
 25 
Elizabeth C. Wayne*, Siddarth Chandrasekaran*, Michael J. Mitchell, Maxine F. 26 
Chan, Rachel E. Lee, Chris B. Schaffer, and Michael R. King. TRAIL-coated 27 
leukocytes that prevent the bloodborne metastasis of prostate cancer.  28 
 29 
 30 
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5.1 Introduction 38 
Prostate cancer (PCa) is the second most common cancer in men, with an estimated 39 
1.1 million new men diagnosed with prostate cancer and 307,000 deaths worldwide in 40 
2012 [1]. When detected at an early stage, the 5-year survival rate for PCa is close to 41 
100%. In contrast, if diagnosed at a late stage with advanced metastatic disease, the 5- 42 
year survival decreases to 33% [1].While effective therapies exist to treat primary 43 
tumors of the prostate, metastatic disease is generally considered incurable [2]. The 44 
primary tumor sheds tumor cells into the circulation, which can then transit through 45 
the bloodstream to form metastases in tissues of the bones, liver, lung, and other 46 
organs [1,3]. Clinically, the detection and quantification of circulating tumor cells 47 
(CTCs) in PCa patient blood samples before and after treatment is a strong predictor 48 
of patient survival – indeed, chemotherapies that cause a net reduction of CTC count 49 
from above, to below 5 cells per 7.5 mL of blood (as measured via CellSearch 50 
technology) are correlated with improved survival outcomes [4,5]. However, the direct 51 
targeting of CTCs as a means to interrupt the metastatic process has gone largely 52 
unexplored. 53 
 54 
TRAIL is a promising cancer therapeutic because of its ability to induce apoptosis in 55 
tumor cells but not normal cells. Since the discovery of TRAIL there have been 56 
numerous preclinical trials that showed promising anticancer activity. These results 57 
led to the use of TRAIL-receptor agonists (TRAs) in dozens of clinical trials. 58 
Unfortunately, the outcomes failed to research their early promise. Primary reasons 59 
cited for this failure include the selection of TRAs that were well tolerated but tended 60 
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to have lower agonist activity and the realization that many primary cancer cells 61 
exhibit resistance to TRAIL therapy. Consequently, there has been a push for 62 
developing higher-order configurations of TRAIL to increase potency and for 63 
developing chemical sensitizers.  64 
 65 
Despite these early disappointing results in treating solid tumors, TRAIL has special 66 
potency for treating metastasis and in particular inducing apoptosis to circulating 67 
tumor cells within the bloodstream. Previous studies suggest that genetic expression of 68 
TRAIL is decreased in anchored tumor cells and further that detachment of tumor cells 69 
from the primary tumor sensitizes cells to apoptosis [6-8]. Moreover, blocking 70 
integrin-mediated cell adhesion has been found to cause increased sensitivity to 71 
TRAIL apoptosis [9]. When considering the physiologic conditions of the blood 72 
circulation, tumor cells show increased sensitivity to TRAIL-mediated apoptosis 73 
within the shear stress environment of the blood circulation. Tumor cells exhibited 74 
greater TRAIL-mediated apoptosis proportional to higher shear stress conditions in a 75 
manner that was not recapitulated when treating cells with doxorubicin [10]. Based on 76 
this collective evidence, technology that can maximize TRAIL capacity to bind to 77 
circulating tumor cells could prove to be quite beneficial.  78 
 79 
Immune-based therapies are a promising alternative to radiation and chemotherapy 80 
treatment of prostate cancer. Currently, the standard of treatment includes radical 81 
prostatectomy, hormone injections, radiation therapy and chemotherapy [2,11]. The 82 
success of these therapies is often limited, as many patients become resistant to 83 
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conventional therapies once the primary tumor has metastasized [12]. Prostate cancer 84 
lends itself to immunotherapies owing to the strong interaction of host immune cells 85 
with prostate cancer cells. Nanomedicine combined with immunotherapy approaches 86 
is becoming more attractive as formulations offer customizable functionality, 87 
improved pharmacokinetics, and targeting specificity. Functionalizing leukocytes to 88 
carry therapeutic nanoparticles has gained attention within the last decade.  Largely, 89 
these have taken the form of ex vivo manipulations of immune cells. However, few if 90 
any studies have utilized immune cells themselves as a carrier for anti-tumor agents. 91 
 92 
Recently, we described a unique nanomedicine approach to target and kill CTCs 93 
within the flowing blood [13]. Nanoscale liposomes were conjugated with two 94 
proteins: E-selectin (ES), a vascular adhesion molecule important in inflammation that 95 
binds to carbohydrate ligands on all leukocytes and many types of CTCs, and TRAIL, 96 
a protein produced by immune cells that induces apoptosis in cancer cells but has 97 
minimal effect on normal cells. When injected into the bloodstream, ES/TRAIL 98 
liposomes attach to the surface of peripheral blood leukocytes, which then become 99 
cytotoxic to any cancer cells present in the blood. Under physiological flow 100 
conditions, this results in near complete elimination of viable cancer cells within 2 h of 101 
shearing human blood samples ex vivo, or following liposome and cancer cell 102 
injection into the mouse circulation. The aim of the current study was to determine 103 
whether ES/TRAIL liposomes could be effective in preventing new metastatic tumor 104 
formation in a more realistic model of metastasis: one in which a primary tumor grows 105 
and then begins to shed CTCs into the bloodstream, which subsequently colonize 106 
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distant organs. Orthotopic models of prostate cancer have been widely characterized 107 
[14-17] and used to investigate the effect of new therapeutics in mice. In this study, we 108 
demonstrated the prevention of metastatic tumor development in an orthotopic 109 
xenograft model of PCa, through the sustained delivery of ES/TRAIL liposomes 110 
designed to induce apoptosis in circulating tumor cells.  111 
 112 
5.3 Materials and Methods 113 
Preparation of sterile ES/T liposomes 114 
Multilamellar liposomes, composed of egg L-α-lysophosphatidylcholine (Egg 115 
PC), egg sphingomyelin (Egg SM), ovine wool cholesterol (Chol), and 1,2-dioleoyl- 116 
sn-glyc- ero-3-[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl] (nickel 117 
salt) (DOGS NTA-Ni) at weight ratios 60–50%:30%:10%:10% (Egg PC/Egg 118 
SM/Chol/DOGS NTA-Ni), were prepared using a thin lipid film method. DOGS- 119 
NTA-Ni is a lipid conjugated to nickel-nitrilotriacetic acid (Ni-NTA) that allows for 120 
attachment to his-tagged proteins. Briefly, stock solutions of all lipids were prepared 121 
by dissolving powdered lipids in chloroform to produce a final concentration of 5 122 
mg/mL Egg PC, 20 mg/mL Egg SM, 5 mg/mL Chol, and 20 mg/mL DOGS-NTA-Ni 123 
in glass containers and stored at −20°C. Appropriate volumes of the lipids were taken 124 
from the stock solution to make lipids in a glass tube and gently dried under nitrogen. 125 
To ensure complete removal of chloroform, the lipids were left under vacuum for an 126 
additional 12 h. The lipid film was hydrated with a liposome buffer composed of 150 127 
mM NaCl, 10 mM Hepes, and 1 mM MgCl2 dissolved in nuclease-free water to create 128 
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multilamellar liposomes. The resulting multi- lamellar liposomes were sized by 129 
repeated thawing and freezing, and then subjected to 15 extrusion cycles at 60°C 130 
through two different pore size (200 and 100 nm) polycarbonate membranes 131 
(Nucleopore; Whatman) to produce unilamellar nanoscale liposomes. A standard 132 
autoclaving cycle (15 min, 121°C) was used to sterilize the liposomes after pumping 133 
N2 gas into the liposomes in glass ampules to remove oxygen that can cause liquid 134 
oxidation. The ampules were then placed in a vacuum degasser to remove residual air 135 
and then transferred to autoclave chambers for sterilization. No change in pH or size 136 
of the liposomes was observed after autoclaving. The sterilized liposomes were 137 
allowed to cool to 4°C and then conjugated with recombinant human TRAIL and ES 138 
as described previously. ELISA was used to determine the final concentration of ES 139 
and TRAIL on liposomes (R&D Systems). To remove unbound TRAIL and ES, 140 
liposomes were diluted 1:6 with liposome buffer and subjected to ultracentrifugation 141 
at 100,000 × g for 6 h at 4°C. The mean particle diameter and surface charge (zeta 142 
potential) were measured by dynamic light scattering using a Malvern Zetasizer nano 143 
ZS (Malvern Instruments Ltd.), according to the manufacturer’s protocols. 144 
Unconjugated liposomes were measured to be 103.4 ± 10.3 nm in diameter, with a 145 
zeta potential of −3.5 ± 2.3 mV before autoclaving and 104.7 ± 17.2 nm in diameter, 146 
with a zeta potential of −5.3 ± 1.1 mV after autoclaving. Conjugated liposomes were 147 
measured to be a 120.5 ± 5.7 nm in diameter with a zeta potential of -8.3 ± 4.0 mV. 148 
The negative zeta potential upon autoclaving could be attributed to the redistribution 149 
of phospholipids within the lipid bilayer [18]. The conjugation of proteins on the 150 
liposome surface further reduces the zeta potential, which could minimize their 151 
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interaction with negative plasma proteins in circulation [19]. This change was 152 
expected, as the liposomes were not PEGylated and protein conjugation on non- 153 
PEGylated liposomes have been shown to reduce the surface charge by other groups 154 
[20].  155 
 156 
ELISA was used to determine the final concentration of ES and TRAIL on 157 
liposomes. Unconjugated proteins were removed by ultracentrifugation and liposomes 158 
were dissociated using 0.1% Triton X-100. The dissociated liposomes were then 159 
diluted at 1:10, 1:100 and 1:1000 with liposome buffer and coated on 96-well ELISA 160 
plates, and a protocol supplied by the manufacturer was used to determine the 161 
concentration of ES and TRAIL using appropriate calibration curves created with 162 
standard ES and TRAIL provided with the ELISA kit. 163 
Pharmacokinetics of ES/T liposomes 164 
Freshly prepared nanoscale liposomes were conjugated with recombinant E- 165 
selectin (ES) (16 ng/mL final concentration) and TRAIL (8 ng/mL final concentration) 166 
for 30 min at 37°C and then overnight at 4°C, to ensure maximum protein binding via 167 
the interaction between his-tag on recombinant proteins and Ni-NTA on liposomes. To 168 
determine the circulation half-life of ES/TRAIL liposomes in the peripheral 169 
circulation of mouse, male NOD.CB17-Prkdcscid/J mice (6-8 weeks old, Jackson 170 
Laboratories) received retro-orbital injections of either ES/TRAIL liposomes or ES 171 
liposomes (120 μL per mouse). At t=3, 36 and  72 hr three mice were sacrificed to 172 
ensure maximum blood draw by cardiac puncture. Blood from three mice were pooled 173 
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for each time point and peripheral polymorphonuclear and mononuclear cells were 174 
isolated by density centrifugation on Histopaque-1077 (Sigma Aldrich). About, 1x106 175 
purified leukocytes were incubated for 45 minutes in dark at 4°C with APC 176 
conjugated anti-CD45 (eBioscience), a pan-leukocyte maker and its corresponding 177 
isotype control (eBioscience). To verify liposome binding to circulating leukocytes, 178 
leukocytes were labeled with FITC conjugated anti-human TRAIL (BD Biosciences) 179 
and analyzed using a Guava easyCyteTM flow cytometer. At 72 hr, labeled leukocytes 180 
were imaged using a Zeiss confocal microscope to verify liposome binding to 181 
circulating leukocytes. Appropriate isotype controls were used for all flow cytometry 182 
experiment to determine the gating procedure.  183 
 184 
Prostate Orthotopic Implantation  185 
Male NOD.CB17-Prkdcscid/J  (Jackson Laboratory) mice 6-8 weeks old were 186 
used for this study. Animals were placed under anesthesia using 5% isoflurane. 187 
Isoflurane was reduced to 2% after the animal was completely anesthetized.  Animals 188 
were shaved and cleaned using repeated iodine solution and 70% ethanol swabs. Using 189 
sterile scalpel, a low midline abdominal incision about 1-3mm wide was created 190 
through the skin and muscle layer. The ventral lobes of the prostate were located and 1 191 
million D-luciferase labeled DU145 cells suspended in 50uL PBS were injected into 192 
the prostate gland using a 30G needle. Muscles and skin layers from the abdomen 193 
wound were closed separately using Vetbond Tissue Adhesive (3M). Animals were 194 
monitored every 8 hr and given analgesic medication for 3 days post surgery. Animals 195 
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were housed in pathogen free conditions and all procedures are done under sterile 196 
conditions in approval from Cornell IACUC. 197 
ES/TRAIL Liposome Treatment  198 
Beginning at three-weeks post tumor implantation, animals received retro- 199 
orbital injection of, E-Selectin/TRAIL (ES/T), E-Selectin only (ES), or liposome 200 
buffer (Buffer).  Treatment was administered once every three days and in alternating 201 
eye sockets. Injections were performed under 2% isoflurane anesthesia and the eyes 202 
were protected via application of eye ointment.  203 
 204 
Circulating Tumor Cell (CTC) Enumeration 205 
After 9 weeks post-implantation, blood was collected from three mice in each 206 
treatment group via cardiac puncture using a heparin-coated syringe. Blood samples 207 
were carefully layered over 3 mL Histopaque-1077 (Sigma Aldrich) and centrifuged at 208 
480 × g for 50 min at room temperature. The buffy coat containing mononuclear cells 209 
and cancer cells was recovered and washed twice in resuspension buffer, collected, 210 
and placed into culture at 37°C and 5% CO2 under humidified conditions for 6 hr in a 211 
24-well plate. The number of CTCs was determined for mCherry positive DU145 cells 212 
in culture. Fluorescent micrographs were taken at 100 randomly selected locations 213 
within each well, and total DU145 cells were estimated based on the total well area 214 
and reported as the number of cells per mL of blood in Figure 3.  215 
 216 
 217 
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Bioluminescence Imaging 218 
Post tumor implantation, animals were monitored weekly for bioluminescent 219 
activity. Luciferin was administered at 150mg/kg per animal via intraperitoneal 220 
injection using 30G insulin syringe needle. Animals are placed under anesthesia using 221 
2% isoflurane and imaged 5 min post injection for maximum bioluminescence signal. 222 
Images were taken at 1 s exposure time using a Xenogen IVIS 200 Imaging System. 223 
For the quantitative measurements of average radiance, the area of the primary BLI 224 
was constant throughout all time points for each animal.  225 
 226 
For the ex vivo organ quantitative measurements of BLI activity, luciferin was 227 
injected into the animal 5 minutes before euthanasia. After euthanasia, organs were 228 
immediately removed and placed in warm PBS containing luciferin. Once all organs 229 
were collected, the organs were arranged on a black sheet and imaged for 120 s for all 230 
samples. Each animal was imaged within 5 min post euthanasia for optimal detection 231 
of luciferase activity. Luminescence imaging data was acquired using a luminescence- 232 
imaging box custom-built by staff at the Cornell University Biotechnology Resource 233 
Center. 234 
 235 
Individual bioluminescent organ intensities were summed across each image 236 
and divided by the number of pixels using a custom Matlab code. Background signal 237 
was subtracted from each image. Representative images from each treatment group 238 
were displayed.  239 
 240 
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Liver Enzyme Measurement 241 
Human hepatocytes have shown sensitivity to TRAIL at sufficiently high 242 
dosages and we measured the serum levels of alanine aminotransferase (ALT) and 243 
aspartate aminotransferase (AST) to assess liver function in treated mice. These 244 
proteins, if present in elevated levels in serum, indicate leakage from damaged cells 245 
due to inflammation or apoptosis. These enzymes normally reside inside the cells and 246 
any damage to the liver cells usually represents hepatocellular damage. Serum levels 247 
of ALT and AST were analyzed using a colorimetric assay kit (BioVision). 248 
Hematocrit 249 
Blood was drawn via cardiac puncture using a 28G heparin coated syringe and 250 
collected in a heparinized tube. Two drops per animal were placed in hematocrit tubes 251 
and spun for 2 minutes using CritSpin Microhematocrit Centrifuge. The ratio of red 252 
blood cells to total blood volume was used to calculate the hematocrit.  253 
 254 
Weight 255 
Every animal was weighted at least once per week throughout the duration of 256 
the experiment. Control animal weight was contributed from Jackson Laboratory 257 
website information about this specific strain. There were no significant differences in 258 
animal weight between the treatment groups.  259 
 260 
Histology 261 
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After bioluminescence imaging, samples were transferred to 4% PFA, stored 262 
overnight and then transferred to 30% sucrose in PBS. Samples were then submitted to 263 
the Cornell Histology Lab for H&E staining and scoring by a veterinary pathologist.  264 
For scoring purposes the pathologist had no knowledge of which animals belonged to 265 
which treatment groups. Representative images were acquired for presentation.  266 
 267 
TUNEL staining was performed on 20-micron thick sections that were incubated in 268 
TUNEL-mix (Roche) at 37°C from 60 min. A DAPI counterstain was applied for 3 269 
min to label nuclei. Fluorescent images were acquired immediately after staining and 270 
the image exposure time was kept constant for each channel throughout each treatment 271 
group.  272 
 273 
5.3.1 ES-TRAIL liposome coated leukocytes remain in circulation for 274 
greater than 96 hrs 275 
To determine an appropriate timescale for ES-TRAIL treatment, we performed 276 
pharmacokinetic studies to determine the half-life of ES-TRAIL in circulation. Blood 277 
cells were isolated from mouse blood following injection of liposome treatment 278 
groups. Flow analysis was performed to identify the population of cells expressing 279 
CD45, a widespread marker for leukocytes, and human TRAIL. It was determined that 280 
within 30 min, nearly 100% of leukocytes stained positive for human TRAIL (Fig. 1). 281 
Since soluble TRAIL has been widely reported by other scientists as well as in our 282 
previous publications to have a half-life <30 minutes and ineffective against 283 
circulating tumor cells, a soluble TRAIL treatment group was not included.  By 72 hr, 284 
only 10% of leukocytes maintained surface TRAIL (Fig. 1). The half-life was thus 285 
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estimated to be ~35hrs. Based on the pharmacokinetics presented, animals were 286 
treated every 72 hr.  287 
 288 
In a separate experiment, confocal imaging was used to confirm that 72 hr post 289 
injection ES/TRAIL liposomes remained bound to the leukocyte surface and had not 290 
been internalized (Fig. 1). In addition, the confocal images suggest that the 291 
exponential decrease in ES/TRAIL coated leukocytes is not due to the shedding or 292 
unbinding of ES/TRAIL liposomes from the leukocyte membrane (Fig.1B). Rather, 293 
the half-life is likely linked to the lifespan of circulating leukocytes themselves. As an 294 
example, neutrophils are the most abundant leukocyte population and have a short 295 
half-lifeof 6-8 hours [21]. Thus, we expect that the emergence of new cells and the 296 
death of older cells contribute to the decrease in populations of ES/TRAIL liposome 297 
labeled leukocytes. 298 
299 
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 300 
 301 
 302 
 303 
Figure 5.1 Pharmacokinetic dynamics of TRAIL-coated leukocytes. 304 
(A) Scatter plots showing percentage of circulating mouse leukocytes staining positive 305 
for surface bound human TRAIL protein. (B) Confocal micrograph of a mouse 306 
leukocyte presenting human TRAIL protein on its surface at t=72 hours (Scale bar = 307 
10μm).  308 
309 
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 310 
5.3.2 ES/TRAIL liposome coated leukocytes result in reduction in size 311 
of the primary tumor 312 
 313 
Dual labeled DU145-luc-mcherry prostate cells were orthotopically injected 314 
into the prostate of NOD-SCID animals (Fig. 2A). We observed that CTC populations 315 
were detectable after 4 weeks (Fig. 3) and decided to begin treatment in the 316 
proceeding week (Fig. 2B). Mice were sorted by primary tumor size at week 2, and 317 
three tumor size-matched groups of mice (n=8 each) were formed. The experiment 318 
was terminated at week 9 as a humane endpoint, as several of the mice in the two 319 
control groups (buffer treatment, ES liposomes without TRAIL) showed visible signs 320 
of distress such as skin lesions and lethargy. At week 9, whole animal BLI showed the 321 
widespread presence of metastatic tumors throughout the abdominal cavity in the two 322 
control groups, with no macroscopic metastases visible in the ES/TRAIL treatment 323 
group (Fig. 2C). Remarkably, ES/TRAIL liposomes also caused significant reduction 324 
in the growth rate of the primary tumor (Fig. 2D), with no BLI signal detectable in 325 
treated mice when imaged from the dorsal side (Fig. 2C). This difference in treatment 326 
group is likely due to ES-TRAIL liposome exposure to the cells in the primary tumor 327 
due to leukocyte infiltration as is typically associated with cancer inflammation [22]. 328 
Our previously published data indicated that ES liposomes may keep CTCs in 329 
circulation by blocking the ES-mediated adhesion of CTCs to the endothelium [23]. 330 
The difference in the average radiance between the ES-only and Buffer treatment 331 
groups, though not significantly different, suggests that leukocytes functionalized with 332 
ES liposomes may also be interacting with cells within the primary tumor.  In this 333 
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light, the stark difference in primary tumor growth between ES and ES/TRAIL treated 334 
animals corroborates that ES binding facilitates adhesion to cancer cells and, when 335 
combined with the apoptosis inducing TRAIL, leads to efficient cancer cell death.  336 
337 
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 338 
 339 
Figure 5.2 Test of ES/TRAIL liposomes to prevent metastasis in an 340 
orthotopic model of prostate cancer. (A) Schematic of orthotopic xenograft 341 
model for metastatic prostate cancer progression. (B) Timeline for ES/T liposome 342 
efficacy trial in tumor-bearing mice. (C) Whole animal BLI of the ventral (left) and 343 
dorsal (right) side of representative animals from each treatment group at the end of 344 
the trial (week 9) (D) Average radiance from the primary tumor. Comparisons were 345 
made via one-way ANOVA with Tukey posttest. Error bars represent the mean ± SD 346 
at each timepoint. ES vs ES/TRAIL: %=(p < 0.05)  %%=(p<0.01). Buffer vs 347 
ES/TRAIL: **=(p<0.05).  348 
 349 
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 350 
Figure 5.3 Quantification of bioluminescence signal of DU145 cells 351 
following orthotopic tumor implantation. (A) Increased bioluminescence 352 
signal from tumor growth over time. (B) Bioluminescent signal from excised organs 5 353 
weeks after tumor implantation (left) and age-matched control (right). (Scale bar = 354 
1cm) (C) Confocal micrographs of buffy coat isolated from control mice (age-matched 355 
non-tumor bearing SCID mice) and mice bearing orthotopic DU145 tumor six weeks 356 
after implantation (blue, cell nuclei and red, mCherry expressing DU145 cells). (Scale 357 
bar = 100μm) (D) Number of CTCs per volume of blood, measured weekly after 358 
orthotopic implantation of tumor. n=3 mice were analyzed each week. Error bars 359 
represent the mean ± SD at each timepoint. 360 
 361 
 362 
 363 
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5.3.3 ES/TRAIL functionalized leukocytes reduce the number of 364 
circulating tumor cells in a prostate orthotopic tumor model  365 
 366 
In a previous publication, we showed that ES/TRAIL functionalized leukocytes were 367 
able to kill over 90% of CTCs within 2 hrs of circulation time using COLO 205 368 
human cancer cells [23]. In the current study, we seek to determine whether 369 
ES/TRAIL liposomes were successful in eliminating CTCs over a sustained period of 370 
time where there was already an established primary tumor. For this study we used a 371 
different cancer cell line and found that DU145 cells also undergo apoptosis when 372 
exposed to ES/TRAIL liposomes in blood (Supplementary Fig. 2).   Blood was 373 
collected from all mice at the end of the in vivo study to quantify number of CTCs. 374 
Quantitative comparison of the CTC count in buffer-treated mice (~1,600 CTCs/mL 375 
blood) vs. ES/TRAIL liposome-treated mice (~100 CTCs/mL blood) shows a 376 
difference of about 94% (Fig. 4A). Representative fluorescent images reveal dramatic 377 
decrease in collected CTCs from ES/TRAIL liposome-treated mice (Fig. 4B). 378 
379 
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 380 
 381 
Figure 5.4 ES/TRAIL liposome treatment is effective in significantly 382 
reducing the number of circulating tumor cells in blood. (A) Average 383 
number of CTCs in the peripheral circulation post treatment. n=3 mice for each group. 384 
Bars represent mean + SD for each group.  (B) Representative fluorescent 385 
micrographs showing mCherry positive DU145 cells isolated from whole blood of 386 
animals from different treatment groups at the end of the study. Scale bar = 100μm. n= 387 
6, 6, 6, and 3 for treatment groups ES/T, ES, Buffer, Buffer(ES/T), respectively. Error 388 
bars represent the mean ± SD in each group.  ***p<0.0001 389 
 390 
391 
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 392 
To determine the effect of ES/TRAIL liposomes on untreated blood with high tumor 393 
burden, 3 animals from the Buffer-treatment group were treated with a single dose of 394 
ES/TRAIL (indicated as Buffer (ES/T)). Remarkably, this single dose resulted in a 395 
greater than 50% reduction in CTC count  (Fig.  4A). Furthermore, the dramatic effect 396 
of a single late-stage dose of ES/TRAIL suggests that CTC targeting could yield 397 
therapeutic benefit to patients even at later stages associated with high CTC count. 398 
Taken together with the absence of metastatic tumors observed in ES/TRAIL 399 
liposome-treated mice (Figs. 5 and Supplementary Fig. 1), this indicates that CTC 400 
targeting need not be 100% effective in order to achieve the clinically significant 401 
outcome of metastasis prevention. That is, by tipping the scales and reducing the 402 
metastatic load in the peripheral circulation to a fraction of its untreated numbers, the 403 
inherent inefficiency of the metastatic process could take over to benefit the patient. 404 
Likely, these remaining CTCs undergo anoikis and immune clearance and lack 405 
sufficient numbers to successfully colonize distant organs. 406 
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 407 
Figure 5.5 Ex vivo BLI analysis reveals that ES/TRAIL liposomes 408 
block widespread metastasis. (A) Representative BLI images reveal the spread 409 
of DU145-Luc cells to lung, liver, kidney and spleen across Buffer, ES, and ES/T 410 
treatment groups (left-to-right). Scale bar=1cm. (B) Bioluminescent signal from each 411 
organ was quantified for each treatment groups: Buffer (n=8), ES-liposomes (n=6), 412 
and ES/T (n=6). Data are plotted on a log scale. Individual data points represent total 413 
organ signal from an individual animal. Superimposed box plots bound the 25th to 414 
75th percentage of all data points and the whiskers extend 1.5 times the interquartile 415 
range beyond boxes. *P<0.05, **P<0.01 (one-way ANOVA with Tukey posttest).  416 
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5.3.4 Ex-vivo organ analysis reveals reduction in metastasis in ES- 417 
TRAIL treated animals.  418 
 419 
To determine whether ES-TRAIL was successful in reducing metastases, we 420 
assayed growth of tumors in distant organs. Organs removed for ex vivo BLI analysis 421 
revealed widespread proliferation of luciferase-expressing DU145 cancer cells in the 422 
lungs and liver, kidneys and spleen of the buffer-treated and ES liposome treated 423 
control mice (Fig. 5A) with virtually no signal above background in ES/TRAIL 424 
liposome treated mice (Fig. 5B). All images were taken at the same exposure. Each 425 
image is a composite of the black and white camera photo and bioluminescence signal. 426 
Difference in organ coloration is due to natural organ pigmentation in addition to 427 
variations in the presence of blood at the time of organ harvesting.  428 
 429 
While the present study was principally focused on suppressing the 430 
development of bloodborne metastasis, a significant decrease in primary tumor size 431 
was also observed (Supplementary Fig. 1), together with a reduction in the presence of 432 
abdominal visceral metastases observed at the organ boundaries in untreated mice. 433 
This suggests that TRAIL-coated leukocytes, such as lymphocytes, enter into the 434 
visceral fluid of the peritoneal cavity and the primary tumor. The presence of 435 
lymphocytes is consistent with the well-documented leaky phenotype associated with 436 
the NOD.CB17-Prkdcscid/J mouse line and is confirmed with our previous 437 
characterization of ES liposome binding to nearly all leukocyte subtypes [23]. Hence, 438 
decorating leukocytes with ES/TRAIL liposomes can provide the additional benefit of 439
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drug delivery to tumors by attaching drug to cell populations that will intrinsically 440 
aggregate in the region of disease.  441 
 442 
Histology was performed on all organs and interpreted by an independent 443 
veterinary pathologist, with results found to be consistent with the BLI analysis 444 
(Supplementary Fig. 3).  Specifically, metastatic prostate carcinoma was found in the 445 
lung, diaphragm, liver and peri-adipose tissue of the kidneys and spleen in buffer and 446 
ES liposome treated animals, with some minimal evidence of scattered neoplastic cells 447 
in the lungs and liver of ES/TRAIL treated animals.  448 
 449 
5.3.5 Toxicity studies indicate little negative effects with ES-TRAIL 450 
liposome treatment 451 
 452 
The dosage of TRAIL used in the ES/TRAIL liposome formulation represents 453 
~1.0% of the concentrations that were well tolerated in previous animal and human 454 
trials with soluble TRAIL protein [24,25], and so consistent with our prior study we 455 
did not expect to see evidence of toxicity [23]. We examined for common signs of 456 
TRAIL toxicity observed in previous rodent trials featuring extremely high doses of 457 
TRAIL [26,27]. Indeed, mice treated with 15 consecutive doses of ES/TRAIL 458 
liposomes showed no evidence of: (Fig. 6A) elevated liver enzymes in the serum; (Fig. 459 
6B) significant difference in hematocrit relative to untreated mice; (Fig. 6C) loss of 460 
appetite or body weight or behavioral distress compared to untreated mice; (Fig. 6D); 461 
or enlarged kidney mass (Fig. 6E). It should be noted that two mice in the treatment 462 
group died within hours of liposome injection in week 5, which we attribute to 463 
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imperfect liposome sterilization since local retro-orbital inflammation was 464 
immediately evident and no characteristic signs of TRAIL toxicity were noted in these 465 
animals. In a previous pilot study, 100% of liposome-treated animals experienced such 466 
acute sepsis before our liposome sterilization procedures were improved to include an 467 
autoclaving step prior to protein conjugation. Future work with these materials should 468 
utilize current Good Manufacturing Processes that are not currently available to our 469 
laboratory. 470 
471 
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 473 
Figure 5.6 ES/TRAIL treatment does not induce toxicity. (A) Serum 474 
levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) liver 475 
enzymes in mice from different treatment groups and aged matched controls at the end 476 
of the study. Bars represent mean + SD for enzyme levels from three mice in each 477 
treatment group. (B) AST/ALT ratio for mice from different treatment groups and 478 
aged matched controls. AST/ALT >2 indicates liver toxicity. (C) Systemic hematocrit 479 
of mouse blood. Each dot represents the hematocrit measurement from an individual 480 
animal. Blood was drawn prior to euthanasia. Control group (Control) represents age- 481 
matched and strain-matched animals that received no tumor or drug. (D) Weight of 482 
animals throughout the experiment. Each dot represents the average weight (grams) of 483 
each animal. Control group represents age-matched and strain-matched animals that 484 
received no tumor or drug. (E) Weight of excised organs post-mortem. (F) TUNEL 485 
staining of liver from ES/T liposome and Buffer treated animals. Error bars represent 486 
mean + SD of each treatment group. NS= non-significant difference.  Comparisons 487 
made using one way-ANOVA.  *p<0.01, **p<0.001. 488 
 489 
 490 
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5.4 Discussion  491 
In this paper, we present an innovative scheme for TRAIL presentation to treat 492 
metastatic disease by specifically targeting circulating tumor cells. Past preclinical 493 
studies and clinical trials have focused on delivery of TRAIL variants to treat solid 494 
tumors, rather than metastatic cells within the bloodstream [28,29]. In fact, CTCs are 495 
mostly valued as predictors of disease progression rather than a bottleneck of 496 
metastasis that are available for targeting. Our study explicitly demonstrates that 497 
directly eliminating CTCs can reduce metastasis disease in secondary organs.  498 
 499 
The therapeutic effect is due to the liposomal-bound TRAIL presentation on 500 
the surface of leukocytes and amplified binding opportunities between TRAIL and 501 
CTCs mediated by margination in the bloodstream. TRAIL is a membrane bound 502 
protein expressed on the surface of natural killer cells. Liposomal carriers increase 503 
therapeutic efficacy by presenting TRAIL in its natural, membrane-bound state. No 504 
further cleavage or activation of TRAIL is necessary for this formulation. We have 505 
also shown that ES/TRAIL liposomes are stable in whole blood isolated from healthy 506 
volunteers. In our previous work we established that ES/TRAIL liposomes can 507 
effectively target cancer cells spiked into whole blood collected from healthy 508 
volunteers under physiologically relevant shear stress conditions, recapitulated in a 509 
cone-and-plate viscometer [23]. The ES/TRAIL liposomes were effective under 510 
different hematocrit levels, indicating their stability in whole blood. 511 
 512 
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Past and present works support these findings that the therapeutic potential of 513 
TRAIL is increased even in TRAIL resistant cancer cell lines—without the use of 514 
sensitization agents—when presented on lipid bilayers [30]. Furthermore, the fluid 515 
dynamics of blood flow cause an effect called margination that results in increased 516 
binding/contact opportunities between ES/TRAIL coated leukocytes and CTCs. In the 517 
fluid shear stress microenvironment of the blood circulation, larger, less deformable 518 
objects are deflected away from the center and towards the vascular wall. Both CTCs 519 
and leukocytes are both relatively large cells and bind to ES ligands to roll along the 520 
vascular endothelium. It is in this environment that these cells are able to undergo 521 
repeated collisions and TRAIL that is bound to leukocytes has more opportunities to 522 
bind to CTCs. It should also be noted that TRAIL liposomes tethered to the surface of 523 
circulating leukocytes exhibited a circulation half-life (Fig. 1) significantly longer than 524 
any previously described nanoparticle formulations of TRAIL [31-33]. Nanomedicine- 525 
based therapeutic approaches such as the one demonstrated here may hold the key to 526 
exploiting the potency of TRAIL within the circulation.  527 
 528 
In addition, many cell-based therapies are rising in popularity due to their 529 
natural ability to migrate toward and penetrate inflamed regions that are often difficult 530 
to achieve with drug delivery mechanisms. The mechanism presented here is unique 531 
because it does not require any ex vivo-based manipulations of immune cells for 532 
enhanced therapeutic effect. In this way, one is able to avoid donor harvesting, 533 
specific activation and production challenges associated with adoptive T cell therapies 534 
and cell-mediated drug delivery, which carries drug nanoparticles internally. Since 535 
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many other common cancers such as those derived from breast, lung, colon and skin 536 
are known to metastasize through the bloodstream [34]  and given the dramatic 537 
decrease in the number of CTCs after only one dose, ES/TRAIL liposomes could be 538 
administered clinically as a preventative measure for newly diagnosed patients. Most 539 
cell types exhibit some level of apoptosis response to the TRAIL ligand [35], 540 
nonetheless, should a specific tumor prove to be completely resistant to TRAIL 541 
therapy, scores of studies have been published over the past 15 years that report new 542 
chemical agents (chemotherapeutics, inhibitors, natural products) that are able to 543 
sensitize cancer cells to TRAIL-mediated apoptosis [36]. 544 
 545 
Future work should focus on testing the efficacy of ES/TRAIL liposomes in 546 
other models of bloodborne metastatic cancer, and the ex vivo testing of patient- 547 
derived CTCs under physiologic blood flow conditions. While E-Selectin is a broad 548 
target for leukocytes, further specificity can be gained by using ligands specific for 549 
leukocyte subpopulations such as NK killer cells, B-cells and T-cells that are current 550 
promising targets in cancer immunotherapy. Finally, it should be noted that while our 551 
focus has been on cancer metastasis, this drug delivery mechanism could be applied to 552 
other diseases where there is substantial leukocyte infiltration such as 553 
neurodegenerative diseases.  554 
 555 
5.5 Supplementary Figures 556 
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 557 
Supplementary Figure 5.1 Representative whole-body 558 
bioluminescence images from three treatment groups.  559 
Representative images from Buffer (row 1), ES (row 2), and ES/TRAIL (row 3) from 560 
13 days through 60 days past tumor implantation. Images reveal stagnant primary 561 
tumor growth of ES/TRAIL treated animals. 562 
 563 
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  564 
Supplementary Figure 5.2 DU145 cells express death receptors and 565 
undergo apoptosis when sheared with ES/TRAIL liposomes in blood. 566 
(A) Flow cytometric analysis of DU145 cells for death receptor (DR4 and DR5) 567 
expression. (B) Number of viable DU145 cells per volume of blood after treatment 568 
with ES/TRAIL or ES liposomes in blood under shear flow. n=3 for all samples. Bars 569 
represent mean +/- SD in each group. (C) and (D) Flow cytometry of DU145 cells 570 
without and with ES/TRAIL treatment in a cone-and-plate viscometer at 188 s-1 for 2h.  571 
 572 
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 573 
Supplementary Figure 5.3 Hematoxylin & eosin stained sections from 574 
various organs in each treatment group. Black arrows point to regions of 575 
neoplastic colonization within the organ parenchyma. The diaphragm in ES/T 576 
liposome treated animals were found to be free of tumor burden, in contrast to ES 577 
liposome and Buffer treated animals with widespread tumor growth as indicated by 578 
asterisks. A similar tumor burden pattern was observed in the peri-adipose tissue 579 
surrounding the kidneys (see asterisks). (Scale bar = 200µm) 580 
581 
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CHAPTER 6 707 
ROLE OF MICROGLIA IN THE EARLY STEPS OF BRAIN 708 
METASTASIS 709 
 710 
 711 
 712 
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 728 
Brain metastases are a devastating event with poor prognosis, often occurring 729 
in the final stages of disease progression.  Nearly 20% of all cancer patients will 730 
develop a brain metastasis and that number is increasing because of longer overall 731 
survival of patients. The majority of brain metastases originate from lung (40%, 50%), 732 
melanoma (10%), and from unknown primary origin (10%, 14%) and breast (15%, 733 
30%), in men and women, respectively (1-3). Treatment options for brain metastasis 734 
include tumor resection and radiotherapy.  Prognosis is poor and typical survival after 735 
treatment is 3-6 months (4).   736 
Despite the success of current therapies in reducing tumor growth, there is inevitably a 737 
small population of tumor cells that evade original tumor therapy causing eventually 738 
disease recurrence. These surviving cells gain de novo protection through interaction 739 
with the microenvironment and can eventually develop acquired drug resistance 740 
against existing therapies. Furthermore, there is evidence to support that highly 741 
metastatic cancer cells are most differentiated by their ability to interact with the host 742 
microenvironment(5, 6). In a chick embryo study by Morris et al., the extravasation 743 
rates between cancer cell lines of varying metastatic potential were found to be 744 
equivalent (95% of all cells extravasated within 3 days of injection), however, the 745 
ability of cells to migrate and proliferate post extravasation was significantly different 746 
(5). In an in vivo mouse model, cholesterol emboli were able to extravasate into the 747 
brain parenchyma within 3 days suggesting that there are passive mechanisms of 748 
vascular recanalization that support extravasation of anything occluding vessels, 749 
whether cancer cell or other emboli (7, 8). Thus understanding the role of the tumor 750 
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microenvironment has never been more vital for treating cancer metastasis. The host 751 
microenvironment is the final frontier of cancer metastasis. In particular, the 752 
inflammatory response of the brain environment is a potential target for therapy and 753 
has been shown to be involved in primary brain tumor formation and metastasis 754 
development (9-11). In this chapter, I will discuss the role of microglia in maintaining 755 
the brain environment, review previous animal models for studying microglia 756 
involvement in brain metastasis, and finally summarize the preliminary results of the 757 
interaction between circulating tumor cells and microglia during extravasation, 758 
dormancy, and/or proliferation in the brain microenvironment. 759 
 760 
The role of microglia in the brain microenvironment 761 
The brain is a tightly regulated environment. The blood brain barrier prevents 762 
passage of small molecules and blocks transport of circulating immune cells into the 763 
brain parenchyma. Because of this lack of outside support, the brain has a network of 764 
specialized internal cells that protect the brain against possible injury including 765 
astroyctes, microglia, pericytes, perivascular macrophages, and oligodendrocytes.    766 
Microglia1 are but one of those cell populations and are activated in many 767 
neurodegenerative diseases such as multiple sclerosis, Parkinson’s disease, stroke, 768 
gliomas. What role they play in brain metastasis remains poorly understood.  769 
Microglia are the specialized innate immune cells of the brain. They provide 770 
continuous surveillance of brain and serve to protect the brain against foreign 771 
                                                
1 Bloodborne macrophages, often abbreviated as mo-MΦ , are also play some role in 
neurodegenerative diseases (Figure 6.1), however, the main focus of this thesis chapter 
is on brain resident microglia.  
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pathogens and injury as well as to mediate repair. Upon sensing a brain injury/insult, 772 
microglia undergo rapid activation that manifests via migration, morphological 773 
change, and increased phagocytosis and secretion activity (Figure 6.1). Microglia are 774 
the most common glial cell in the brain and make up at least 10%-12% of the total 775 
brain cell population in mice(12, 13). While microglia are the most common, they are 776 
also the most unique cell population of the brain. Unlike neurons and astrocytes, 777 
microglia are territorial and do not form permanent contacts with other microglia (14, 778 
15).  Microglia have extended processes that do not overlap and their regional density 779 
corresponds inversely with the density of other cell populations in the brain (i.e. lower 780 
microglia density in regions with high density of neural cell bodies). This strategy 781 
seems to benefit the brain; in this configuration microglia are able to scan the entire 782 
brain environment at least once every few hours (13, 16). A 2005 time-lapse in vivo 783 
study by Nimmerjahn et al. masterfully demonstrated the rapid scanning activity of 784 
microglia in their “resting state”, finding that microglia extensions and retractions 785 
occur at up to 4.1 μm/min (13).  786 
 787 
788 
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 790 
Figure 6.1 Microglial and mo-MΦ functions – cascade of events. (a) 791 
Resident microglia originate from yolk sac macrophages that repopulate CNS 792 
parenchyma during early development and are self-renewed locally, independent from 793 
bone marrow-derived monocytes, by proliferation of primitive progenitors. (b) In the 794 
steady state microglia are constantly scanning their environment through their highly 795 
motile processes. These cells facilitate the maintenance of synapses (c) and 796 
neurogenesis (d), as well as secrete growth factors essential for normal CNS 797 
performance (e). Upon recognition of a danger signal, microglia retract their branches, 798 
become round and ameboid, and convert into an activated mode (f). A short or 799 
moderate signal directs microglia toward a neuroprotective phenotype; these cells 800 
clear debris by phagocytosis (g), secrete growth factors associated with remyelination 801 
(h) and support regeneration (i). Intensive acute or chronic activation renders 802 
microglia neurotoxic; under such conditions microglia fail to acquire a neuroprotective 803 
phenotype. Instead, these cells produce reactive oxygen species (ROS), nitric oxide 804 
(NO), proteases, and pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α, all 805 
of which endanger neuronal activity (j). Microglial malfunction results in the 806 
recruitment of mo-MΦ to the damage site (k). mo-MΦ secrete anti-inflammatory 807 
cytokines such as IL-10 and TGF-β, express factors associated with immune 808 
resolution such as manose receptor and arginase 1 (ARG1), and promote 809 
neuroprotection and cell renewal (l), all of which are functions that cannot be 810 
provided, under these conditions, by the resident microglia. Adapted and expanded 811 
from London et al. (2013). 812 
 813 
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Microglia are extremely versatile cells. Microglia exhibit different functional 817 
capabilities; gene array and real-time PCR studies suggests there are subset 818 
populations of microglia that form the reactive phenotypes that characterize microglial 819 
activation(17-19). Scheffel et al., activated microglia via LPS stimulation and found 820 
MHCI, TNFα, COX, and CCL3 induction as established in previous publications, 821 
however flow cytometer analysis reveals the induction is coming from a small subset 822 
of microglia (20). Immunohistochemical staining showed that the activated cells 823 
appears to be distributed arbitrarily and did not correlate to a particular morphology.  824 
LPS injection into different brain regions exhibited different levels of microglia 825 
activation, alluding to a regional level of microglia response (21). Microglia differ in 826 
their ability to recognize and respond to pathogen and possess differing abilities of 827 
cytokine secretion and phagocytosis (Figure 6.2). Exploring this topic of 828 
heterogeneity could be linked to heterogeneous response of microglia to invading 829 
tumor cells that has been found in past studies.  830 
 831 
 832 
 833 
 834 
 835 
 836 
 837 
 838 
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 840 
FIGURE 6.2 Schematic summary of examples indicating microglial response 841 
heterogeneity. (A) Stimulation of microglia cells with neurotransmitters and 842 
neurohormones triggering calcium signals revealed that only small fractions responded 843 
to each compound. Combined stimulation and population analysis thereby suggested 844 
an enormous variety in terms of functional receptor expression. (B) Exposure to LPS 845 
induced a panpopulational expression of major histocompatibility complex I (MHCI) 846 
molecules, indicating that all microglia expressed TLR4. In contrast, only subsets also 847 
produced TNFα and/or CCL3. (C) Treatment of microglia with IFNγ caused the 848 
expression of major histocompatibility complex II (MHCII) in some but not all cells. 849 
On the other hand, MHCII-expressing microglia did not clear myelin-laden exosomes, 850 
a function that rather associated with MHCII-negative cells. (D) Exposure of cells to 851 
myelin debris resulted in the phagocytic uptake of the material in a subset of 852 
microglia. Adapted and expanded from Scheffel et al. (2012).  853 
 854 
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6.1 Microglial Activation in Cancer  857 
Microglia have a complex, far from uniform response to brain metastases, 858 
exhibiting both tumor supportive and tumor destructive properties (22-26).  Lorger et 859 
al, injected various human cancer cell lines into immune-compromised and immune- 860 
competent mice and showed that microglia presented amoeboid morphology around 861 
some cancer tumor cells clusters but ramified, seemingly non-activated morphology 862 
around others (22). Further this difference in morphology was present at early stages 863 
as well as near tumor growths 50 days post tumor cell injection. Because of the 864 
heterogeneous response the role of microglia activation in tumor development 865 
remained unclear. Using organotypic brain slice models which are discussed later in 866 
the chapter, Pukrop et al, demonstrated the microglia can assist invading cells by act 867 
as guiding rails to enable invasion of surrounding parenchyma and that there is less 868 
invasion when microglia or inactivated (27). Results have also shown microglia can 869 
exhibit anti-tumor effects. Microglia possess the ability to lyse human cancer cells via 870 
release of nitric oxide (28).  LPS activated microglia have been shown to have 871 
cytotoxicity activity to lung cancer cell in vitro (29). Unfortunately, most of the 872 
studies demonstrating tumor destructive behaviors by microglia are in vitro. Using in 873 
vivo studies, microglia appear to not be activated in this manner and both genetic and 874 
IHC analysis show that brain metastasis associated microglia have an immune- 875 
suppressive phenotype that supports tumor growth (26, 30).  876 
However, there is an inherent flaw in this reasoning—successful metastases 877 
will undoubtedly be surrounding by tumor-supportive microglia whereas non- 878 
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successful metastatic events (and thus potential tumor-destructive microglia) will go 879 
unobserved and unevaluated.  In order to unmask the role of microglia in brain 880 
metastases, there needs to be tracking of all metastatic events. The heterogeneous 881 
response to brain metastasis may be related to the heterogeneous distribution of 882 
phenotype of microglia themselves. The manner in which microglia respond to 883 
circulating tumor cells may be depend on location of arrest and extravasation as well 884 
as the intercellular signaling between CTCs and the brain microenvironment. In order 885 
to address this hypothesis, there needs to be an effective in vivo animal approach that 886 
can not only track the interaction of CTCs and microglia upon initial arrest but can 887 
quantify whether or not each individual metastatic event leads to a successful 888 
metastatic tumor.  889 
 890 
6.2 Animal Models to study microglia activation 891 
 Tracking single tumor cells during stages of metastasis is a very important 892 
question that scientists have tried to tackle for decades. Primary tumors are very 893 
heterogeneous, so understanding what obstacles CTCs encounter and discerning which 894 
mechanisms enable successful cells to complete metastasis can yield more information 895 
about how to treat tumors. The ability to track tumor cells has been heavily coupled to 896 
the advancement of technology in imaging, which has been outlined in (Table 1). 897 
Early studies were geared towards naturally amenable models such as using optically 898 
transparent models, or highly vascularized animal models such as chick embryos and 899 
zebrafish. However, while these models offer great information about intravasation, 900 
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extravasation, and angiogenesis, they do not recapitulate other stages in metastasis 901 
very well. Below is a description of the models used to understand metastasis.  902 
Organotypic models are a co-culture of thick brain slices with tumor pieces to 903 
capture invasion and interaction of cancer cells with the brain host cells (11, 31-33). 904 
They are reproducible systems that can be fluorescently labeled for imaging purposes 905 
and pharmacologically modified. These co-cultures exclude circulation, which can be 906 
advantageous when seeking to isolate the role of resident brain cell populations. The 907 
culture can practically be sustained for up to 2 weeks, making it unfavorable for 908 
visualizing longer-term tumor progression.  909 
Histology studies using in situ mouse models have been also been used to track 910 
tumor cells (9, 22, 34, 35). The benefit of in situ analysis is that you can label a nearly 911 
unlimited number of cell populations or soluble factors that are not feasible in vivo. 912 
Lorger et al, injected various cancer cells into mice and identified astrocytes and 913 
microglia as the most reactive cells population to invading tumor cells (22). The most 914 
obvious limitation is that you are not able to investigate the fate of observed cells.  915 
Intra-vital window implants in mice have facilitated visualization of nearly all 916 
stages of metastasis (36, 37). Many models have emerged for visualizing metastasis 917 
including in the brain (7, 36, 37), liver (38) and skin flap (39, 40). In the case of 918 
studying proliferation or invasion, organ windows are extremely strategic because you 919 
can choose the tumor origin. However for intravenously injected CTCs or models that 920 
spontaneously shed CTCs from a primary tumor, tracking cells dynamics is much 921 
more challenging. CTC arrest in vasculature is stochastic, making this model not as 922 
reproducible and streamlined. In addition, this method is very laborious and surgery 923 
 131 
intensive, and requires specialized optical techniques. Overall, this is the model that 924 
offers the most accurate, most unaltered opportunity to visualize single CTC 925 
metastasis into a secondary organ. 2PEF has greatly enabled this progress in single 926 
cell visualization within an intact, living organism. In 2009, Kienast et al., was able to 927 
track cancer cell arrest, extravasation, migration, regression and/ or proliferation (36). 928 
Furthermore, Kienast et al. used this model to demonstrate that of the 150-200 cancer 929 
cells tracked only roughly 2% of those formed successful metastasis. This is the model 930 
used for studying CTC interaction with microglia cells in the brain. 931 
932 
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 933 
 934 
 935 
Model Advantages Disadvantages Reference 
Artificial or 
Spontaneous 
CTCs 
Models 
 
• High resolution 
• Mimic circulation of 
tumor cells 
• Stochastic CTC arrest. 
Rely of probability of 
seeing cell 
• Technically complex 
(7, 8, 36) 
Orthotopic 
Window 
• User decides location of 
tumor origin and imaging 
window placement 
• Difficult to visualize 
later stages of 
metastasis 
(6, 41) 
Organotypic • Isolate parenchymal 
microglia from 
bloodborne /peripheral 
macrophages 
 
• Allow selective 
environment changes (i.e. 
testing of 
pharmacological agents or 
cell populations) 
• Limited ex vivo 
culture window, only 
viable for ~2weeks 
• In vitro, missing early 
steps of metastasis 
(11, 27, 31-
33, 42, 43) 
Zebrafish • Optically transparent 
• Uniformly patterned 
vasculature facilitates 
CTC detection 
• Supports human cancer 
cells 
• Non-invasive 
• Amenable for genetic and 
pharmacological 
alterations 
• Non-mammalian 
model 
(44-48) 
Chick • Highly vascularized (ideal 
for extravasation studies) 
• Ideal thickness for optical 
imaging 
Non-mammalian model (5, 6, 49, 50) 
     Table 6.1 Models of CTC Metastasis 936 
937 
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The role of the host microenvironment and in particular, the role of microglia 939 
in metastasis remains elusive due to the lack of evidence in vivo showing the 940 
progression of a tumor cell to a successful metastatic growth, or to a failure to 941 
establish a new tumor. In the brain there are in vivo studies have shown the importance 942 
of vessel co-option in CTC metastasis in an in vivo mouse model (36). In this 943 
remainder of this chapter, I discuss the relevance of microglia activation in 944 
neurodegenerative disease and how my preliminary results of cancer metastasis fit into 945 
the paradigm. This chapter will serve as a guide for future attempts to study microglia 946 
involvement in cancer metastasis. I conclude with some comments on the model and 947 
future directions.  948 
 949 
6.3 Microglia respond to occlusions via morphological transformation 950 
Microglia undergo a fast morphological transformation, altering their shape 951 
from a ramified, resting state to a shape with a larger soma, thicker, short, or more 952 
directed processes, and in the final stage to a fully amoeboid phagocytic state (Figure 953 
6.1). Remarkably, these morphological transformations can occur within mere 954 
minutes, depending on the injury. Attempts have been made to quantify microglia 955 
morphology in order to develop classifications or stages within the microglia’s 956 
transition from fully ramified to fully amoeboid. Area, perimeter, roundness, convex 957 
perimeter, number, thickness, and length of processes are few of the morphological 958 
parameters that have been analyzed (12, 33, 51-53). In addition, the dynamic behavior 959 
of microglia such as process extension, retractions have been characterized extensively 960 
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(13).  Such methods to quantify microglia morphology may add more cohesiveness 961 
and validity to the literature by means of reducing the vagueness of describing 962 
microglia activation.  963 
In vivo imaging of invading circulating tumor cells reveal that microglia 964 
respond quickly to circulating tumor cell arrest via morphological changes. In 965 
particular, the soma, the main body of the microglia, increase in size over time 966 
(Figure 6.3).  Microglia monitored over time in non-CTC injected animals show 967 
stable levels of microglia size, indicating that change in size may be due to CTC 968 
arrest. When measuring individual microglia size changes over time (Figure 6.3 C), 969 
we found that not all microglia are increasing in size, or at the same rate. This is an 970 
interesting finding because it yields more evidence to the idea that microglia are not 971 
identical. 972 
 973 
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 975 
 976 
         Figure 6.3 Microglia Size Increases Over Time.  A) 2PEF images of microglia 977 
(green) soma size increase within an hour after CTC (red) injection.  B) Quantification 978 
of soma size increase over time.  C) Lines represent trajectory of individual microglia 979 
size change.  The microglia represented here were all within a 150μm radius. 980 
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 981 
Microglia near the CTC increased in size over time. We also found that this increase 982 
in size was dependent on the initial distance of the microglia to the invading CTC. A 983 
plot of microglia size vs. distance from the CTC (Figure 6.4) shows that the largest 984 
microglia are closest to the CTC and that microglia generally decrease in size with 985 
increasing distance. This would suggest that microglia may be responding to a 986 
chemical and/or physiological gradient induced by the CTC.  This corroborates 987 
previous data that suggest microglia are the earliest responders to brain metastasis 988 
(23). 989 
990 
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Figure 6.4 Microglia increase in size as a function of distance from Invading CTC 993 
A plot of microglia size versus radial distance from arrested CTC (blue). For 994 
comparison of microglial size, microglia size as function of distance from an arbitrary 995 
spot in a control animal were measured (green).    996 
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6.4 Microglia form phagocytic cups around circulating tumor cells  1011 
 1012 
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Perhaps the most iconic form of activation for a macrophage would be 1013 
phagocytosis (17, 54-56). Microglia, being the macrophages of the brain, are known 1014 
for clearing apoptotic neurons or debri as a natural process in brain development and 1015 
during neurodegeneration (54, 57). However, microglia also perform this role (or fail 1016 
to) in many neurodegenerative diseases.  1017 
In our in vivo model of metastasis, microglia are observed to phagocytose cell 1018 
and/or cell debris. The phagocytosis event occurred on relatively short time scales, 1019 
only 2 hours (Figure 6.5). Phagocytosis appears to occur via engulfment by a 1020 
phagocytic cup, a structure that has been seen in other studies(58-61), where microglia 1021 
extend their processes around a cell. The results herein are preliminary due to the 1022 
small sample number, however, observations of phagocytosis has been rare but 1023 
important in understanding mechanisms the brain uses to eradicate tumor cell 1024 
populations.  Interestingly, the same morphological and migration activities 1025 
demonstrated in previous sections are also occurring in this phagocytic example.  As 1026 
the microglia “corner” the CTC, they exhibit increased soma sizes over time and 1027 
visually appear to have fewer and/or thicker processes.  1028 
1029 
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 1030 
 1031 
 Figure 6.5 Microglia phagocytosis.  Microglia (green) migrate toward an invading 1032 
CTC (white) in the brain. Vessels (red). By 2hrs the CTC has disappeared leaving only 1033 
the remnants of the phagocytic “cup” formation as shown at (t=130 min).  1034 
1035 
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6.5 Comments on the Model  1037 
Imaging circulating tumor cell extravasation into the brain parenchyma is a 1038 
powerful tool for understanding how metastasis occur. This model yields insight into 1039 
the tumor-destructive behaviors of microglia that go unnoticed in other models. 1040 
However, as mentioned previously, the random nature of CTC arrest in brain 1041 
vasculature is one of the most challenging aspects of the study.  Of the 150 1042 
documented attempts, including both in vivo and histology-based analysis of ICA 1043 
injections of cancer cells; only around 5 resulted in positive identification of CTCs in 1044 
the brain. Furthermore, for the animal studies performed in vivo, all mice died within 1045 
24 hours after the imaging sessions, limiting the ability to track dynamics of CTCs 1046 
post vasculature arrest. It should also be noted that neither ICA injection of cancer 1047 
cells alone or ICA injection of saline followed by imaging results in premature death. 1048 
The combination of ICA cancer cell injections and subsequent imaging resulted in 1049 
poor likelihood of animal survival. This unintended death is likely due to cancer cells 1050 
lodging into other vital organs in a manner supported by the blood flow changes 1051 
associated with prolonged isoflurane anesthesia.  1052 
There are several possible experimental design reasons for this low success 1053 
rate. This study was designed to use an immune-competent mouse cancer model to 1054 
account for the positive role of the immune system and enable use of syngeneic cancer 1055 
cell lines. In this case, using C57Bl6 transgenic mice and C57Bl6 derived melanoma 1056 
and prostate cell lines. The majority of publications that study brain metastasis have 1057 
used immune-deficient mice and human cancer cell lines. The difference was thought 1058 
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to be insignificant, however, the high failure rate suggests that there are more complex 1059 
interactions involved than initially thought. For example, B16F10 melanoma cells 1060 
have been shown to preferentially proliferate in the meninges and ventricles of the 1061 
brain (35) and as such, these cells did not home to brain parenchymal tissue where 1062 
they could be observed in intravital microscopy. Although the RM1 prostate cell line 1063 
had no strong tropisms, detection of these cells were also difficult.  1064 
Experiments where micrometer-sized beads are injected into the ICA reveal 1065 
that size restriction plays a big role in initial arrest in the brain vasculature.  1066 
Obstructing brain blood flow by ICA injection of polystyrene beads is a classic model 1067 
for testing the impact of size restriction on brain inflammation and changes in blood 1068 
flow (62-64).  Larger sized beads were more likely to remain in vasculature after 3 1069 
days than small sized beads (Figure 6.6 and Figure 6.7). In addition, the number of 1070 
beads injected affected the number retained in vasculature. Even with larger beads that 1071 
have a higher probably of arresting in vasculature were found in low quantities when 1072 
fewer beads were injected. While one can increase the number of cancer cells injected, 1073 
this may also result in undesirable pathologies that hinder the ability to study the 1074 
microenvironment of cancer metastasis such as stroke and pulmonary embolism.  This 1075 
was observed when injecting over 200,000 mouse or human cancer cells and when 1076 
injecting over 5,000 fluorescent 25 µm beads. Mouse cancer cell lines can be smaller 1077 
than human cell lines (Figure 6.8). Given the data previously stated, objects smaller 1078 
than 10μm in diameter are likely to clear the brain and lodge into other parts of the 1079 
body. The smaller size of mouse cancer cells may be the most significant risk factor 1080 
causing premature death in our in vivo mouse experiments. This yields important 1081 
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information for the models of metastasis being chosen and how to choose cancer cell 1082 
lines and animal models.  1083 
To highlight the stochastic nature of emboli retention in the brain, we further 1084 
quantified the number of fluorescent beads that were found in a region likely to be 1085 
visibly using 2PEF microscopy. The results mirrored those found overall but with 1086 
even fewer beads found. In addition, while the fluorescent beads were useful for 1087 
understanding retention patterns in the brain, the beads lodged by mechanical 1088 
restriction and therefore lack the ability to actively interact with the environment as a 1089 
cancer cells would. The added complexity that cancer cells were also lodge in regions 1090 
because they prefer the environment further complicates the ICA injection model for 1091 
imaging brain metastasis.  1092 
 1093 
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Figure 6.6 Effect of Emboli Size and Injection Amount on Retention in 1095 
Brain   Fluorescent beads of 10µm (A), 15µm (B), and 25µm (C) were injected via 1096 
intra-carotid artery into the brain of C57Bl6 mice. After 3 days, brains were harvested 1097 
for sectioning and quantitative analysis. (D) Macroscopic image of fluorescent beads 1098 
lodged in an intact brain. Courtesy: Evan Bander.  1099 
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 1107 
Figure 6.7 Distribution of beads near cortex surface.   Quantification of total 1108 
number of beads observed in brain vs number of beads found near cortex surface. (A), 1109 
(B) Example of fluorescent bead depicted as being close to cortex surface.   1110 
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Figure 6.8 Measurement of Human and Mouse Cancer Cell Lines    Diameter of 1126 
human breast cancer cells (MDA-MB-231) and mouse prostate cancer cells (RM1).  1127 
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6.6 Conclusions  1131 
 Overall, tracking circulating tumor cell fate as it attempts to proliferate in a 1132 
secondary organ can yield vital information for understanding why cancer therapies 1133 
fail. 2PEF microscopy is the best method to observe these cell-cell interactions 1134 
because of its superior resolution and ability to image deep into scattering tissue.  1135 
Microglia are remarkable cells in the brain that within a short time scale sense and 1136 
respond to invading cancer cells in a manner that if controllable can have wide 1137 
sweeping outcomes for treatment of not only brain metastases but primary brain 1138 
tumors and possibly other neurodegenerative diseases where microglia activation is 1139 
involved.  1140 
Future work should explore using tracking CTCs in the metastatic environment 1141 
over longer periods of time. Many of the difficulties with such a study are technical; 1142 
work should be devoted towards streamlining the experimental processes of imaging a 1143 
stochastic process. Ideas include, priming growth of tumors cells with tropism for 1144 
regions of organs that are optically accessible, and developing imaging acquisition 1145 
algorithms that allow for faster and automated data collection. Developing organ 1146 
specific tumors, while still artificial has the benefit of allowing the operator to inject 1147 
cells in less invasive manners such as tail vein or cardiac injection. In addition, future 1148 
work should explore using a CTC model with emboli rather than single cell events. 1149 
The advantage here is twofold: large objects are more likely to lodge in a region 1150 
observable via 2PEF microscopy, and furthermore, embolus is a more relevant 1151 
presentation of how CTCs travel in the bloodstream.  1152 
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Finally, imaging is a vital tool to understand spatial and temporal dynamics, 1153 
however there are features of the tumor microenvironment that cannot easily be 1154 
fluorescently labeled such as cytokine signaling. Now that we have a sense of how 1155 
microglia response, the cytokine secretion aspect of microglia activation should be 1156 
investigated to understand what factors are causing microglia to respond.  1157 
  1158 
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CHAPTER 7 1333 
CONCLUSION AND FUTURE DIRECTIONS 1334 
  1335 
1336 
 154 
 Cancer is a devastating and costly disease to treat and affects over 14.5 million 1337 
Americans every year with an estimated 1,620 deaths per day [1]. The current cancer 1338 
treatment paradigm uses therapeutics that limit tumor growth and because of this 1339 
inherently cannot prevent metastasis because it only addresses the final stage of 1340 
metastasis.  While some therapies attempt to inhibit particular facets of metastasis 1341 
development, they are often given after other treatment options have failed and the 1342 
disease is much more resistant. It should then be no surprise that metastasis accounts 1343 
for over 90% of cancer deaths. The future treatment of cancer must create more 1344 
therapies that address prior stages of cancer metastasis and do so at an earlier time in 1345 
patient treatment. Addressing circulating tumor cells (CTCs) is an ideal stage of 1346 
metastasis to target because it is a population of convergence for the spread of cancer.  1347 
Furthermore, tumors that are treated before distant metastasis has formed have over a 1348 
remarkable 60% increase in overall survival prognosis in nearly all-epithelial cancers.  1349 
Eliminating the CTCs population is both the secret and the solution to treating cancer 1350 
metastasis.  1351 
 1352 
Using advanced preclinical animal models of cancer metastasis, combined with 1353 
bioluminescent and two-photon imaging modalities, the work in this dissertation 1354 
addresses circulating tumor cells as a therapeutic target and the role of the innate 1355 
immune system as a therapeutic carrier. Research to date on CTCs has primarily 1356 
focused on their use as a diagnostic and prognostic indicator. In this thesis, we 1357 
describe an approach to directly target and kill CTCs in the bloodstream that relies on 1358 
coating leukocytes with liposomes that contain both cytotoxic and CTC targeting 1359 
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elements. Circulating leukocytes decorated with TNF-related apoptosis inducing 1360 
ligand (TRAIL) and E-selectin adhesion receptor selectively killed over 75% of CTCs 1361 
within 3 hours in an acute animal model. Moreover, in a 9-week orthotopic prostate 1362 
cancer model ES-TRAIL liposome therapy reduced number of CTCs by over 70% and 1363 
reduced metastasis to other organs as compared to control groups. The use of 1364 
leukocytes as a delivery vehicle for TRAIL increases the potency of TRAIL therapy 1365 
while maintaining low toxicity. The potential for this study has widespread 1366 
implications. Developing a target for CTCs apoptosis makes it a therapy that can be 1367 
used to reduce metastasis across numerous cancers. Given the current drug market 1368 
climate for making highly specific drugs that can benefit a narrow group of patients, 1369 
having a “blockbuster” drug would not only have great success for patient overall 1370 
survival, it would be good in the pharmaceutical market. 1371 
  1372 
In 2000, the role of the immune system was not even included by Weinberg 1373 
and Hanahan’s seminal paper “Hallmarks of Cancer”. In 2011 when the authors 1374 
published Part II, the immune is not only given a larger section but it is listed as 1375 
“Emerging Hallmark” [2]. This is a testament to the exponential advances in cancer 1376 
immunology. Paired with the increase in interdisciplinary research collaborations, the 1377 
field of cancer immunoengineering is ever expanding. In this particular vein, 1378 
knowledge of cancer immunology is paired with drug delivery technology to expedite 1379 
how cells in the immune system recognize and kill cancer cells.  Some key examples 1380 
of immunoengineering are CAR T and ACT cell therapy. Chimeric antigen receptor 1381 
(CAR) T cell therapy modifies harvested T cells with extracellular ligands to enhance 1382 
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T cell cytotoxic activity towards cancer cells.  CAR T cell therapy has shown some 1383 
efficacy in clinical trials, particularly in the treatment of gliomas [3, 4].  Another 1384 
popular immunoengineering technique is Adoptive cell transfer (ACT) Cell therapy 1385 
where donor-harvested cells are selectively passaged for tumor cytotoxicity before 1386 
being introduced back to the recipient. This technique has widely been used in the 1387 
treatment of Multiple Myeloma [5-7].  1388 
 1389 
The ES/TRAIL functionalized leukocyte studies presented within this 1390 
dissertation are a unique type of immunoengineering because the immune cells are 1391 
used as passive carriers that do not require any ex vivo manipulation or activation. 1392 
This makes the therapy all the more attractive as a cancer treatment. In addition, this 1393 
formulation uses TRAIL in its most potent state: in the blood circulation.  TRAIL has 1394 
a long history, which encompasses the promise of a naturally occurring molecule that 1395 
selectively kills cancer cells and unfortunately also includes disappointment from 1396 
dozens of failed Phase III human clinical trials. The work presented here corroborates 1397 
previously published data [8] demonstrating that TRAIL presented on liposomes are 1398 
more effective than in its soluble form. Furthermore, TRAIL is more effective at 1399 
killing isolated, non-adhered tumor cells rather than cells in solid tumors [9-11].  1400 
Goldberg et al., found that anchored cells exhibited reduced expression of TRAIL, 1401 
thereby limiting its therapeutic potential [10]. Directing future TRAIL therapies 1402 
toward circulating tumor cell populations has the potential to re-energize the use of 1403 
TRAIL.  1404 
 1405 
 157 
Pragmatically, future work should include more advanced characterization 1406 
diagnostics. The next steps should be to determine the bio-distribution of ES/TRAIL 1407 
liposomes throughout the mouse as well as the pharmacokinetics of such distribution. 1408 
With what frequency and persistence do ES/TRAIL functionalized leukocytes traffic 1409 
through the lymphatic system and other internal organs? In addition, a more thorough 1410 
understanding of how dosage timing and concentration affect efficacy is needed. As an 1411 
example, at what threshold concentration/percentage of ES/TRAIL functionalized 1412 
leukocytes is the most cytotoxic activity induced?  Finally, we should also investigate 1413 
the long-term effects of ES/TRAIL administration on leukocyte health and behavior 1414 
and blood composition. Understanding the long-term effect of drug treatment on 1415 
leukocytes and the circulating tumor cell population as well as the primary tumor is 1416 
vital.  As mentioned previously, there a small population of CTCs remained. This 1417 
population may be worth comparing to the primary tumor population to determine 1418 
whether any genetic expression alterations occurred that helped these cells evade 1419 
therapy.  1420 
 1421 
If the assertion is correct that ES/TRAIL liposomes are able to functionalize 1422 
the surface of leukocytes anywhere in the body, then this opens a pathway for passive 1423 
but efficient drug delivery. While the primary focus of our studies was drug delivery 1424 
within the blood circulation, one can imagine creating a library of drug bound 1425 
liposomes chosen to target specific immune cell populations. Similar tactics are 1426 
already emerging in the literature through the King Lab and in other laboratories.  1427 
 1428 
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The results of the ES/TRAIL therapy is undoubtedly a success story, however, 1429 
it should be noted that although it demonstrated high efficacy, there remains the 1430 
problem of whether the remaining cell population is sufficient to form a successful 1431 
metastasis. This is true not only for the therapy at hand but for every therapy making 1432 
its way through the preclinical and human clinical pipeline. Though metastasis is an 1433 
inefficient process, it only takes a single cluster of CTCs to form a metastasis. The 1434 
latter part of my thesis explores how CTCs interact with microglia, the innate immune 1435 
cells of the brain, using an in vivo mouse model. Our findings are significant not only 1436 
for treating brain metastasis but for understanding how to think about any therapy that 1437 
may result in a minimal residual disease, a term used to signify the population of cells 1438 
still vital following treatment [12]. The contribution of this study is 1) to set a platform 1439 
for understanding how the fate of individual CTCs events of metastatic spread is 1440 
directly linked to how CTCs are able to evade cancer therapies and 2) to examine the 1441 
role of the host organ microenvironment in facilitating or rejecting CTC invasion. In 1442 
this regard, 2PEF microscopy has been vital to capturing the intercellular interactions 1443 
to comprise the metastatic cascade.  1444 
 1445 
Future work should explore using tracking CTCs in the metastatic environment 1446 
over longer periods of time. Many of the difficulties with such a study are technical; 1447 
work should be devoted towards streamlining the experimental processes of imaging a 1448 
stochastic process. Ideas include, priming growth of tumors cells with tropism for 1449 
regions of organs that are optically accessible, and developing imaging acquisition 1450 
algorithms that allow for faster and automated data collection. Developing organ 1451 
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specific tumors, while still artificial has the benefit of allowing the operator to inject 1452 
cells in less invasive manners such as tail vein or cardiac injection.  1453 
 1454 
Additionally, the findings of our study attempt to link morphological changes 1455 
in the microglia with the fate of CTC metastasis. Next steps should include 1456 
investigating the genetic and molecular changes in microglia caused in response to an 1457 
invading tumor cell. Microglia are known to possess an entire “sensome” of genes, 1458 
which allow them to detect endogenous ligands and respond in either a neuro- 1459 
protective or neuro-toxic manner [13-15]. Potential targets to investigate are markers 1460 
for phagocytosis (CD36 [16, 17], CD14 [18], CD68 [19, 20]), proliferation (IL-34 1461 
[13], M-CSF [21, 22]), and cytokines known to be secreted by microglia (TGFβ1 [23], 1462 
IL-1β [24, 25], TNF-α [26]). Where the methods in used in the study presented in this 1463 
thesis solely used in vivo optical methods, the examination of molecular changes 1464 
would be best done in organotypic co-culture since it is more easily modifiable to 1465 
facilitate antibody labeling and flow cytometry analysis [27].  1466 
 1467 
 In conclusion, there is tremendous promise in immunoengineering and 1468 
understanding the role of the host immune response to cancer metastasis. CTCs have 1469 
more value than simply a cancer diagnostic.  The synergy between nanomedicine and 1470 
biomedical imaging has provided a powerful toolset for understanding how to create 1471 
the next generation of cancer therapy.  1472 
 1473 
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